Cellular, Histological and Behavioral Changes in the Pathogenesis of Hydrocephalus in the Ro1 Mouse Model by McMullen, Allison B.
 
CELLULAR, HISTOLOGICAL AND BEHAVIORAL CHANGES IN THE 
PATHOGENESIS OF HYDROCEPHALUS IN THE RO1 MOUSE MODEL 
 
 Allison Beth McMullen 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Pharmacology. 
 
Chapel Hill 
2011 
 
 
 
Approved by: 
 
Ken D. McCarthy, Ph.D. 
 
T. Kendall Harden, Ph.D. 
 
Gary L. Johnson, Ph.D. 
 
Lee M. Graves, Ph.D. 
 
Patricia F. Maness, Ph.D. 
 
 
ABSTRACT 
 
ALLISON BETH MCMULLEN:  Cellular, histological and behavioral changes in the 
pathogenesis of hydrocephalus in the Ro1 model 
(Under the direction of Ken D. McCarthy) 
 
 Hydrocephalus is a highly prevalent neurological disorder characterized by 
elevated levels of cerebrospinal fluid (CSF) in the brain and subsequent enlargement of 
the lateral ventricles. Currently, the only treatment for this disorder is recurrent 
neurosurgery to insert and revise shunts that drain the CSF. To develop better treatments 
for hydrocephalus, an understanding of the cellular, histological and behavioral changes 
that occur in the pathogenesis of hydrocephalus is required. To this end, we have 
developed a novel model of hydrocephalus, called the Ro1 model, which was created 
using the tetracycline inducible system to direct Ro1 expression to cells expressing glial 
fibrillary acidic protein. This model is unique in that hydrocephalus can be induced at any 
age with complete penetrance and without interfering pathologies, enabling the 
investigation of the earliest pathological changes that lead to hydrocephalus. Also, the 
specific activation of a G-protein coupled receptor (the Ro1 receptor) in a specific subset 
of cells makes investigating signaling pathways involved in hydrocephalus tractable. 
 We discovered that the earliest pathological changes in this model were 
ventriculomegaly and disorganization of the ependymal lining of the aqueduct of Sylvius. 
Thinning and eventual denudation of the ependymal lining was subsequent to 
ventriculomegaly. Additionally, following severe ventriculomegaly, periventricular 
 
edema and areas of the ventricular walls void of microvilli were observed. Stenosis of the 
aqueduct of Sylvius was not present even with severe ventriculomegaly, suggesting that 
the Ro1 model represents a model of communicating hydrocephalus. Interestingly, even 
with severe ventriculomegaly, there were no behavioral changes, possibly due to 
compensation of the brain tissue due to the slow progression of hydrocephalus in this 
model. These data provide insight into the earliest cellular, histological and behavioral 
changes in the pathogenesis of hydrocephalus, which may lead to the development of 
therapeutic treatments for this disorder.  
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Chapter I 
Overview of hydrocephalus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hydrocephalus is a highly prevalent neurological disorder characterized by elevated 
levels of cerebrospinal fluid (CSF) in the brain and subsequent enlargement of the ventricles. If 
left untreated, the buildup of CSF often causes increased intracranial pressure (ICP), resulting in 
the disruption and compression of cerebral structures. In the United States, approximately 1 in 
1000 children are born with hydrocephalus, and approximately 69,000 to 80,000 new cases of 
hydrocephalus are diagnosed each year in both adults and children (Bondurant and Jimenez, 
1995; Patwardhan and Nanda, 2005). Additionally, health care costs related to hydrocephalus 
cost the United States over a billion dollars annually (Patwardhan and Nanda, 2005). Over 50% 
of children with untreated hydrocephalus die within 10 years, and more than 60% of surviving 
children have neurological impairments (McCullough and Balzer-Martin, 1982; Persson et al., 
2007). Currently, there is no cure for hydrocephalus, and the only treatment involves either 
redirecting CSF flow by shunt placement or creating a new pathway for CSF flow. Shunts, first 
developed in 1952, are the predominant treatment for hydrocephalus; however, shunt placement 
surgery has a mortality of 2.7% and two-thirds of shunts fail within 10 years following surgery 
(Patwardhan and Nanda, 2005). As a result, there is a critical need for the development of better 
treatments for hydrocephalus. 
 The lack of pharmacological therapy for hydrocephalus stems, in large part, from the 
multifactorial causes of this disease and the lack of good animal models in which to study 
hydrocephalus. In existing animal models, penetrance is often low and hydrocephalus appears to 
be one of a spectrum of diseases, making it difficult to sort out the cellular mechanisms that are 
specifically contributing to hydrocephalus. Our lab has developed a novel model of 
hydrocephalus that gives us the unique ability to control the onset of the disease and thereby 
study early cellular and morphological changes that lead to the development of hydrocephalus. 
 
This model was created using the tetracycline-inducible system to drive the expression of a 
mutated Gi-coupled G protein-coupled receptor (GPCR; Ro1 receptor) to cells expressing glial 
fibrillary acidic protein (GFAP) (Coward et al., 1998a; Redfern et al., 1999; Scearce-Levie et al., 
2001a; Sweger et al., 2007). When mice are taken off doxycycline (a tetracycline derivative), 
allowing for Ro1 expression in GFAP+ cells, 100% of mice develop hydrocephalus (Sweger et 
al., 2007). Unlike other models, hydrocephalus also appears to be the primary pathology. Due to 
the inducibility, complete penetrance and activation of a specific signaling cascade in a specific 
population of cells, the Ro1 model provides us with the unique ability to study the 
morphological, cellular and behavioral changes that play a role in the pathogenesis of this 
disorder. It is our hope that a better understanding of hydrocephalus obtained through the use of 
the Ro1 model will increase the early diagnosis of this disorder and lead to the development of 
novel therapeutics to treat this disorder. 
 
Chapter II 
 
The Ventricular System 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. Anatomy of the ventricular system 
The ventricular system. Before the pathological changes to the brain and ventricular system 
found in hydrocephalus can be discussed, an understanding of the ventricular system is 
necessary. The ventricular system is composed of four ventricles—two lateral ventricles, a third 
ventricle and a fourth ventricle—through which the cerebrospinal fluid (CSF) flows. CSF, which 
is produced primarily by the choroid plexus found in each of the four ventricles, flows from the 
lateral ventricles through the foramen of Monroe to the third ventricle and travels from the third 
ventricle through the aqueduct of Sylvius to the fourth ventricle. Each lateral ventricle can be 
divided into five regions: the anterior horn, the body, the posterior horn, the temporal horn and 
the collateral trigone (Di Terlizzi and Platt, 2006; Johanson, 2003). The third ventricle lies below 
the lateral ventricles and is irregularly shaped with four recesses known as the optic, 
infundibular, pineal and supra-pineal recesses (Johanson, 2003). The aqueduct of Sylvius also 
has multiple regions, narrowing after exiting the third ventricle and subsequently dilating into the 
ampulla before narrowing into the pars posterior, which dilates as it opens into the lateral 
apertures of the fourth ventricle (Di Terlizzi and Platt, 2006). The fourth ventricle is the most 
caudally located portion of the ventricular system, lying far below the lateral and third ventricles 
and bound by the pons, the medulla oblongata and the cerebellum (Johanson, 2003). The CSF 
flows out of the fourth ventricle through the midline foramen of Magendie and two lateral 
foramina of Lushka, which are located in the roof of the fourth ventricle, into the cisterna magna 
and the basal cisterns of the subarachnoid space, respectively (Brodbelt and Stoodley, 2007; 
McLone, 2004). The cavity of the fourth ventricle also extends into the central canal of the spinal 
cord (Di Terlizzi and Platt, 2006). After exiting into the cisterna magna, the CSF then traverses 
the subarachnoid space over the surface of the cortex and drains back into the blood via the 
 
arachnoid granulations (described below), spinal nerve roots and the olfactory tracts (Brodbelt 
and Stoodley, 2007). The aqueduct of Sylvius, which is the narrowest part of the ventricular 
system, and the foramen of Monroe are the most common sites of blockage in human non-
communicating hydrocephalus (McLone, 2004). The anatomy of the ventricular system is shown 
in Figure 1. 
 
Meningeal structures. The meninges are composed of dura, arachnoid and pia mater, and a fluid-
containing compartment called the subarachnoid space is present between the pia and arachnoid 
layers (Brodbelt and Stoodley, 2007; Haines et al., 1993). The dura mater is the outermost layer 
and is attached to the skull (Haines et al., 1993; Vandenabeele et al., 1996). It is composed of 
fibroblasts, extracellular collagen, elastic fibers and glycoproteins (Brodbelt and Stoodley, 2007; 
Haines et al., 1993; Vandenabeele et al., 1996). The external dura is attached to the inner surface 
of the skull. This layer contains fewer fibroblasts and more extracellular collagen due to the 
network of nerves and blood vessels in the region (Frederickson, 1991; Haines et al., 1993). This 
is in contrast to the inner part of the dura, which has more fibroblasts and proportionally less 
collagen (Frederickson, 1991; Haines et al., 1993). The fibroblasts of this region show an 
elongated and flattened morphology and form a layer that is several cell processes thick and is 
continuous with the arachnoid mater (Alcolado et al., 1988; Haines et al., 1993).  
The arachnoid mater, located immediately internal to the inner dura mater, is a densely 
packed region of cells, called the arachnoid barrier cells, with little extracellular space (Haines et 
al., 1993). These cells are connected by desmosomes, tight and gap junctions, hemidesmoses and 
intermediate junctions, which provide strength for this layer and prevent the movement of fluids, 
large molecular weight substances and ions (Frederickson, 1991; Haines et al., 1993). The 
 
arachnoid trabeculae, specialized fibroblasts that bridge the subarachnoid space and attach to and 
surround traversing blood vessels, exits immediately internal to the arachnoid barrier cells 
(Brodbelt and Stoodley, 2007; Frederickson, 1991; Haines et al., 1993). These cells are attached 
to each other by cell junctions and reinforced by collagen (Brodbelt and Stoodley, 2007; Haines 
et al., 1993). Arachnoid villi are invaginations of the arachnoid into a venous region (Brodbelt 
and Stoodley, 2007; Weed, 1914). These villi penetrate the dura and surround CSF drainage 
veins (Brodbelt and Stoodley, 2007; Tripathi and Tripathi, 1974; Weed, 1914). A large dilation 
of the subarachnoid space within a villus forms an arachnoid granulation, which is found in 
humans older than 18 months (Brodbelt and Stoodley, 2007). Vacuolar, transcellular channels 
found on the arachnoid villi are thought to be a drainage site for CSF, although recently this has 
become controversial (Brodbelt and Stoodley, 2007; Tripathi and Tripathi, 1974). 
The pia mater is formed by a single, continuous layer of flattened fibroblasts lying on the 
surface of the brain, which are attached to the external glial limiting membrane (Alcolado et al., 
1988; Brodbelt and Stoodley, 2007; Haines et al., 1993; Hutchings and Weller, 1986). These 
cells have few cell junctions and surround vessels in the subarachnoid space (Brodbelt and 
Stoodley, 2007; Haines et al., 1993).  Figure 2 shows the structure of the meninges. 
 
The choroid plexus. The choroid plexi (CP) are composed of modified ependymal cells and are 
found in each of the four ventricles, extending from the walls of the lateral ventricles and the 
roof of the third and fourth ventricles (Brodbelt and Stoodley, 2007; Redzic and Segal, 2004). In 
each of these ventricles, the CP forms fine leaf-like projections, with a large surface area of 200 
cm2 (Brodbelt and Stoodley, 2007; Redzic and Segal, 2004). The ependymal lining of the 
ventricles is attached to the CP by a thin stalk and is continuous with the outer covering of the 
 
CP (Redzic and Segal, 2004). The CP is composed by a choroidal epithelium joined by tight 
junctions that form a water-impermeable barrier separating the CSF from the choroidal 
interstitial fluid (Brodbelt and Stoodley, 2007; Redzic and Segal, 2004). The CSF-facing side of 
this epithelium is covered in a dense coat of microvilli, and in some species, long cilia are 
present (Brodbelt and Stoodley, 2007; Kimelberg, 2004; Redzic and Segal, 2004).The CP is 
highly vascularized. In the lateral ventricles, the CP is fed by the anterior choroidal and lateral 
posterior choroidal arteries, while the paired medial posterior choroidal arteries and the posterior 
inferior cerebellar artery supply the CP of the third and fourth ventricles, respectively (Brodbelt 
and Stoodley, 2007; Redzic and Segal, 2004). Within the center of the CP, a complex vascular 
network of large, fenestrated capillaries exists, allowing the flow of small hydrophilic molecules 
into the interstitial fluid of the CP (Redzic and Segal, 2004). The role of the choroid plexus in the 
production of CSF will be discussed below. 
 
Ependymal cells and tanycytes. The ventricles of the brain and the central canal of the spinal 
cord are lined by a continuous layer of ependymal cells with the occasional tanycyte (Brodbelt 
and Stoodley, 2007). Ependymal cells are ciliated cuboidal or columnar epithelial cells, and 
unlike the tight junctions that connect the epithelial cells of the choroid plexus, these cells are 
connected by zonula adherens in the brain and have extensive gap junctions (Brightman and 
Reese, 1969; Brodbelt and Stoodley, 2007; Bruni and Reddy, 1987; Redzic and Segal, 2004). 
Electrophysiologically, ependymal cells are similar to glial cells, possessing high negative 
resting membrane potentials, responsiveness to extracellular potassium levels and low input 
resistances (Bruni, 1998; Jarvis and Andrew, 1988). 
 
Mature ependymal cells have been shown to play a number of roles in the adult brain. For 
example, the coordinated beating of ependymal cilia has been shown to create a current of CSF 
along the walls of the lateral ventricle, and disturbances to the beating of ependymal cilia leads 
to disturbances in CSF flow and hydrocephalus (Banizs et al., 2005; Kobayashi et al., 2002; 
Sawamoto et al., 2006). Interestingly, the beating of ependymal cilia and the CSF currents 
subsequently generated appear to direct the migration of neuroblasts born within the 
subventricular zone from the lateral ventricles to the olfactory bulb in the mouse (Sawamoto et 
al., 2006). Ependymal cells have also been suggested to regulate the transport of ions, small 
molecules and water between the CSF and neuropil (Bruni, 1998), protect the brain from harmful 
substances in the CSF (Kuchler et al., 1994) move cellular debris with bulk CSF flow and 
disperse neural messengers throughout the CSF (Bruni, 1998; Roth et al., 1985). Fetal 
ependymal cells have been suggested to serve a primarily secretory function (Bruni, 1998; 
Sarnat, 1992). Other roles for fetal ependymal cells have also been suggested, including the 
arrest of neurogenesis, axonal guidance, maintenance and transformation of radial glia and the 
transport of nutrients prior to the development of capillary networks (Gould et al., 1990; Sarnat, 
1992). 
Tanycytes, which are specialized ependymal cells primarily found in the third ventricle, 
are interspersed among the ependymal cells (Bruni, 1998). These cells have radially directed 
basal processes that extend into the neuropil and often enwrap blood vessels or terminate on 
neurons, glia or the external glial limitans (Bruni, 1998; Wittkowski, 1998). In the third 
ventricle, tanycytes extend from the floor of the ventricle, where they contact the CSF, to the 
median eminence of the hypothalamus, which suggests a neuroendocrine role for these cells 
(Wittkowski, 1998). 
 
During brain development, the ventricular zone of the brain consists of a psuedostratified 
neuroepithelium that contains multipotent radial stem cells (Jimenez et al., 2009; Spassky et al., 
2005). These radial glia give rise to ependymal cells, which develop along a caudal to rostral 
gradient (Bruni, 1998; Sarnat, 1992; Spassky et al., 2005). In the third ventricle, ependymal cells 
undergo their final division between embryonic days 11 (E11) and E13, and in the lateral 
ventricles, the majority of the ependymal cells are generated between E14 and E16 (Rakic and 
Sidman, 1968; Spassky et al., 2005). Ependyma and cilia formation do not occur until the first 
postnatal week; these events progress caudorostrally and ventrodorsaly along the lateral wall of 
the lateral ventricles of the rodent brain (Spassky et al., 2005). Additionally, differentiated 
ependymal cells are postmitotic, suggesting that these cells are exclusively produced during 
development (Spassky et al., 2005). This finding also explains why the ependymal layer in the 
mammalian brain does not regenerate when injured, as found in severe cases of hydrocephalus 
(Sarnat, 1995). Tanycytes also appear to only acquire their adult form postnatally, maturing as 
late as P34 in rats (Bruni, 1998; Card and Rafols, 1978).  
In humans, ependymal cells begin to differentiate in the floor plate of the neural tube at 
four weeks following gestation. Ependymal differentiation is complete in the lateral and third 
ventricles by 22 weeks following gestation (Bruni, 1998; Sarnat, 1992). Some studies have 
suggested that tanycytes represent a transitional cell type during human fetal development 
(Bruni, 1998; Gould et al., 1990). As these cells differentiate, their processes retract, and they 
eventually become indistinguishable from ependymal cells as they mature (Bruni, 1998; Gould et 
al., 1990). 
 
 
The subventricular zone. Underneath the ependymal cell layer in the lateral ventricles lies the 
subventricular zone (SVZ). The SVZ is comprised of three major cell classes: “A” cells, or 
neuroblasts, astrocyte-like “B” cells, and undifferentiated “C” cells (Doetsch et al., 1997). “B” 
cells are the neural stem cells (NSCs) of the SVZ, giving rise to the intermediary C cell 
population, which then differentiates into the migratory neuroblast, or “A” cell, population 
(Doetsch et al., 1999a). “A” cells migrate in the rostral migratory stream (RMS) to the olfactory 
bulb, where they form new inhibitory interneurons. “B” cells ensheathe the “A” cells in the 
RMS, secrete factors that promote mitotic phases in “A” cells and aid in their migration to the 
olfactory bulb (Lim and Alvarez-Buylla, 1999; Mason et al., 2001). Additionally, “B” cells 
extend processes that integrate into the ependymal layer and contact the ventricular surface as 
well as form connections with the vasculature (Mirzadeh et al., 2008). As a result, “B” cell 
astrocytes are central to the maintenance of the VZ/SVZ due to their close relationship with the 
ependymal layer, their role as the NSC of the SVZ and their role in guiding “A” cell neuroblasts 
to the olfactory bulb. 
 
b. Cerebrospinal fluid function, production, composition and absorption  
Cerebrospinal fluid function. The CSF primarily plays a protective role in the central nervous 
system, providing a stable and specialized extracellular fluid environment for neurons and 
protecting the brain from the fluctuations in arterial and central venous pressure that occur with 
changes in posture, respiration and physical exertion (Bergsneider, 2001; Di Terlizzi and Platt, 
2006; Johanson, 2003). More specifically, the CSF and cerebral blood flow regulate intracranial 
pressure (ICP) by varying inversely to maintain ICP within normal levels despite variations in 
cardiac function and respiration (Di Terlizzi and Platt, 2006). Under physiological conditions, 
 
pressure fluctuations of 1 – 2 mm H2O are associated with the arterial pulse, and fluctuations of 2 
– 5 mm H2O are associated with normal breathing, likely due to the changes in intracranial 
venous pressure associated with breathing (Di Terlizzi and Platt, 2006). In pathological 
conditions in which ICP is elevated, such as hydrocephalus, the CSF pressure fluctuates 
considerably (Di Terlizzi and Platt, 2006). Sudden increases in intracranial blood volume result 
in uptake of CSF into the subarachnoid space, whereas chronic changes are compensated by 
increased absorption of decreased formation of CSF. Rises in ICP due to impairment of these 
compensatory changes result in reduced cerebral blood flow (Di Terlizzi and Platt, 2006).  
 Additionally, the buoyancy of CSF, which is approximately 99% water, protects the brain 
against shearing forces caused by acceleration or deceleration (Johanson, 2003; Redzic and 
Segal, 2004). The CSF reduces the momentum of the brain in response to stresses on strains 
inflicted on the head, thereby reducing injury (Bergsneider, 2001; Johanson, 2003).  By reducing 
the brain’s weight to 25% of its total mass, the CSF also reduces the tension on the nerve roots 
(Redzic and Segal, 2004).  
 The CSF also transports nutrients and biologically active substances, such as hormone-
releasing factors, growth factors, neurotransmitters and neuropeptides, the concentrations of 
which may be altered in pathological states (Bergsneider, 2001; Di Terlizzi and Platt, 2006; 
Johanson, 2003; Podell and Hadjiconstantinou, 1997; Vaughn et al., 1988). Micronutrients that 
are transported in the CSF include vitamins C and B6, folates and deoxyribonucleotides, which 
are actively transported across the CP epithelium and subsequently distributed across the 
ventricular wall and in the subarachnoid space by bulk flow (Johanson, 2003). The large volume 
of CSF also acts as a source of osmolytes for brain volume regulation and a buffer of ions 
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(Bergsneider, 2001). Neurons, in particular, require a consistent ionic composition in the 
extracellular space (Davson and Oldendorf, 1967; Di Terlizzi and Platt, 2006). 
The CSF also plays an important role in the removal of toxic byproducts of cerebral 
metabolism, thereby regulating the chemical composition of the fluids that bathe brain cells 
(Bergsneider, 2001; Di Terlizzi and Platt, 2006; Johanson, 2003). Because the brain lacks a 
lymphatic system, proteins and other substances, such as cells and bacteria, are primarily 
removed via the perivascular spaces and are absorbed through the arachnoid villi into the 
cerebral veins and the lymphatic vessels (Di Terlizzi and Platt, 2006). For example, catabolites 
of serotonin and dopamine, such as 5-OH-indolic acetic acid and homovanillic acid, are actively 
reabsorbed by the CP and cleared by the arachnoid villi, preventing the buildup of metabolic 
waste products in the CSF (Bergsneider, 2001; Johanson, 2003). The CSF also acts to filter 
substances by allowing the movement of water-soluble substances from the parenchyma into the 
CSF (Di Terlizzi and Platt, 2006). 
 
Cerebrospinal fluid production. The CSF is primarily produced by the choroid plexus, the main 
function of which is to secrete CSF, within the lateral, third and fourth ventricles (Brodbelt and 
Stoodley, 2007; Brodbelt and Stoodley, 2007; Redzic and Segal, 2004). The choroid plexi 
produce approximately 60% of the total CSF at a rate of approximately 0.4 ml/min in people and 
3.3 x 10-4 ml/min in mice, and the turnover rate of CSF is approximately 4 and 11 volumes of 
CSF per 24 hours in humans and rats, respectively (Bergsneider, 2001; Di Terlizzi and Platt, 
2006; Johanson et al., 2008). This rate is related to the weight of the CP and the rate of sodium 
and bicarbonate ion exchange (Di Terlizzi and Platt, 2006). The remainder of the CSF is 
produced by the ependymal cells lining the ventricular system, the external pial-glial membrane 
 
of the brain surface and blood vessels in the pia-arachnoid space (Di Terlizzi and Platt, 2006; 
Speake et al., 2001). CSF is formed in the CP by both the passive ultrafiltration of plasma across 
the fenestrated choroidal capillary endothelial wall due to the high degree of vascularization of 
the CP as well as by active secretion by choroidal epithelial cells, which depends on the active 
transport of sodium ions into the ventricles (Bergsneider, 2001; Di Terlizzi and Platt, 2006). CSF 
formation begins by the filtration of plasma across the choroidal capillaries, which is 
proportional to the hydrostatic pressure gradient between the blood and choroid interstitial fluid. 
Thus, the elevated ventricular CSF pressure found in hydrocephalus is transmitted to the 
choroidal ISF, reducing plasma transport into the ISF and thereby decreasing CSF formation 
(Johanson et al., 2008). Fluid and solute exchange is controlled by the barriers of the CP at the 
epithelial cell level (Redzic and Segal, 2004). The zonula occludens that connect the choroidal 
endothelial and epithelial cells permit the passage of most small hydrophilic molecules but limit 
pericellular movement, forming the blood-CSF barrier (Bergsneider, 2001). Additionally, 
peptidases on the apical brush border of the CP provide a metabolic barrier that degrades 
unwanted proteins. Lastly, specific membrane and transport proteins provide a cellular barrier 
that regulates the transcellular movement of fluid and ions to and from the CSF (Brodbelt and 
Stoodley, 2007; Kimelberg, 2004; Redzic and Segal, 2004). Many of these transporters are ATP-
dependent and act to create a gradient of sodium, chloride and bicarbonate ions across the 
epithelial layer of the CP, which drives the unidirectional, transcellular movement of water by 
osmosis through water channels, especially aquaporin 1 (Brodbelt and Stoodley, 2007; 
Gunnarson et al., 2004; Redzic and Segal, 2004). Interestingly, AQP1 knockout mice have 
normal CSF production, suggesting that other transmembrane mechanisms of water transport 
exist (Gunnarson et al., 2004). The production of CSF by the CP is very constant and 
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independent of CSF pressure and blood pressure; as ICP rises, the arachnoid villi allow increased 
flow of CSF into the blood (Di Terlizzi and Platt, 2006). However, in hydrocephalus, in which 
there is chronic increase in ICP, CSF formation may be reduced, possibly due to atrophy of the 
CP (Di Terlizzi and Platt, 2006). 
 
Cerebrospinal fluid composition. The CSF is a clear, nearly acellular liquid, which is 99% water 
(Di Terlizzi and Platt, 2006; Johanson et al., 2008). The composition of the CSF is highly 
regulated by an array of transporters in the CP epithelium. When this regulation fails, normal 
neuronal function is interrupted (Johanson et al., 2008). The CSF contains glucose to supply 
energy to neural cells, and the CSF glucose concentration is generally 60 – 80% of the blood 
glucose concentration. The concentration of glucose in the CSF is dependent on the blood 
glucose concentration, the rate of glucose transport into the CSF and the metabolic rate of the 
central nervous system (CNS) (Di Terlizzi and Platt, 2006). Sodium is the most abundant ion in 
the CSF with a concentration of approximately 158 mmol/L and is important in ion and water 
transport and osmoregulation (Di Terlizzi and Platt, 2006; Johanson, 2003). The potassium 
concentration in the CSF is also critical because it is involved in neuronal function and the 
release of neurotransmitters. It is lower in the CSF than in plasma and is maintained within a 
narrow margin of approximately 3 mmol/L (Di Terlizzi and Platt, 2006). The permeability of the 
epithelium of the CP is greater for sodium than potassium, and the CP regulates the sodium and 
potassium ion concentrations in the CSF through Na+, K+-ATPase pumps (Di Terlizzi and Platt, 
2006). The calcium in the CSF is also lower than in the plasma and ranges from 1 – 1.5 mmol/L, 
and the stability of the calcium ion concentration is also critical for maintaining normal levels of 
neuronal excitability (Di Terlizzi and Platt, 2006; Johanson, 2003). In contrast, magnesium and 
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chloride are found at slightly higher concentration in the CSF than in plasma (1.5 and 138 
mmol/L, respectively) (Di Terlizzi and Platt, 2006; Johanson, 2003). Magnesium and chloride 
play important roles in neuronal conduction (Di Terlizzi and Platt, 2006). 
 To provide support to neural cells, the CSF also contains a full complement of vitamins, 
peptides, nucleosides and growth factors (Johanson et al., 2008). For example, vitamins B and C 
are specifically transported across the CP into the CSF and adjacent neural tissue (Johanson et 
al., 2008). Protein concentrations in the CSF are low and range from 10 – 40 mg/dL in dogs and 
cats as compared to 5 – 7 g/dL in the serum (Di Terlizzi and Platt, 2006). Albumin makes up 50 
– 70% of the protein concentration in the CSF (Di Terlizzi and Platt, 2006). Some enzymes are 
also found in the CSF, and changes in their concentrations are often indicative of neurobiological 
disease (Di Terlizzi and Platt, 2006). Cells, such as lymphocytes and sloughed choroidal 
epithelial, ependymal or arachnoid cells, are rarely found in the CSF in healthy individuals 
(Johanson, 2003). The appearance of ependymal and choroidal cells in the CSF, in addition to an 
increased white blood cell count, is often a sign of disease (Johanson, 2003). Neurotransmitters, 
such as gamma-aminobutyric acid and glutamate, are also found in the CSF. Elevated glutamate 
concentrations are found in several diseases due to the role of glutamate in mediating secondary 
tissue damage (Di Terlizzi and Platt, 2006).  
 Homeostasis of CSF solute composition is critical because even small changes in the ion 
concentrations in the CSF can have a considerable affect on respiration, blood pressure, heart 
rate, muscle tone and emotional state (Di Terlizzi and Platt, 2006; Johanson, 2003). The choroid 
plexus plays a major role in maintaining the stability of these solute concentrations (Brodbelt and 
Stoodley, 2007; Johanson, 2003). The tight junctions between the epithelial cells of the CP act as 
a permeability barrier, blocking bidirectional diffusion of substances between the blood and CSF. 
 
Additionally, the presence of numerous transporters on the CP epithelium allows it to tightly 
regulate the transport of substances across this barrier (Brodbelt and Stoodley, 2007; Johanson, 
2003). Neuropeptides and neurotransmitters can also regulate the secretion of ions, water and 
proteins from the CP. The CP contains a wide variety of receptors, including those for 
norepinephrine, serotonin, angiotensin II and vasopressin (Chodobski and Szmydynger-
Chodobska, 2001; Johanson, 2003; Nilsson et al., 1992). For example, serotonin, vasopressin and 
angiotensin have all been found to inhibit the release of chloride ions from the epithelial cells of 
the CP into the CSF, thereby reducing the formation rate of CSF (Chodobski and Szmydynger-
Chodobska, 2001; Johanson, 2003; Nilsson et al., 1992). Additionally, the superior cervical 
ganglia send adrenergic fibers to the CP, providing an inhibitory tone on CSF formation. When 
sympathetic signals are blocked, there is enhanced CSF production by the CSF; in contrast, when 
 and  adrenergic agonists are administered, CSF production is reduced (Boassa and Yool, 
2005; Cardinali et al., 1981; Johanson, 2003; Lindvall and Owman, 1981). Thus, the CP tightly 
regulates the solute concentration of the CSF by a combination of active transport, facilitated 
diffusion and regulation of neurotransmitter receptors on the CP epithelium (Johanson, 2003). 
 
Cerebrospinal fluid flow. Bulk flow of the CSF occurs from the lateral to third ventricle via the 
foramen of Monro, to the fourth ventricle via the aqueduct of Sylvius and out of the fourth 
ventricle through the midline foramen of Magendie and the lateral foramina of Lushka into the 
cisterna magna (Brodbelt and Stoodley, 2007; Di Terlizzi and Platt, 2006). Pressure gradients 
between the subarachnoid space, venous sinuses and lymphatic spaces as well as movements of 
the brain and spinal cord with changes in blood pressure and respiration contribute to direction 
and pulsatile nature of bulk flow (Bergsneider, 2001; Brodbelt and Stoodley, 2007). 
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Additionally, ependymal cilia appear to help direct CSF flow through the ventricles (Brodbelt 
and Stoodley, 2007). However, there is no net bulk flow down the spinal canal; bulk flow of CSF 
only exists in the ventricular system (Bergsneider, 2001). Maintenance of this flow of CSF is 
important for cerebral metabolism because the CSF supplies micronutrients and peptides to 
neuronal networks and removes catabolites (Johanson et al., 2008). When CSF flow is blocked 
during fetal life, brain development is severely inhibited, partly due to compromised transport of 
growth factors (Miyan et al., 2003). Additionally, reduced CSF flow due to reduced production 
of CSF by the CP during aging and disease results in the buildup of toxic peptides and 
metabolites in the CSF (Johanson et al., 2008; Pratico et al., 2004; Rubenstein, 1998). 
 
Cerebrospinal fluid absorption. CSF is reabsorbed into the systemic circulation by the venous 
system of the arachnoid villi in the superior sagittal sinus, the lymphatic system of the cribiform 
plate above the nose, the nasal submucosa and the olfactory, optic and cranial nerves (VII and 
VIII) (Brodbelt and Stoodley, 2007; Johanson et al., 2008). In recent years, it was demonstrated 
that the arachnoid villi are not the primary site of CSF reabsorption in most mammals, but may 
increase their CSF clearance under pathological conditions that raise ICP, such as hydrocephalus 
(Johanson et al., 2008). However, the arachnoid villi are thought to be the primary site of 
absorption of protein and cells (Bergsneider, 2001). When the ICP is high, brain capillaries may 
also upregulate aquaporin channels, specifically aquaporins 1 and 4, at the CP and brain 
microvessels to absorb interstitial fluid under high pressure (Johanson et al., 2008). In the H-Tx 
and kaolin-induced models of hydrocephalus, aquaporin 4 is significantly upregulated (Bloch et 
al., 2006; Mao et al., 2006; Shen et al., 2006). Reabsorbed CSF drains into the venous blood, and 
hydrocephalus has been associated with impaired extracranial venous obstruction (Johanson et 
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al., 2008; Papaiconomou et al., 2002). Disrupted CSF reabsorption is common in patients with 
communicating hydrocephalus; however, an imbalance between the rates of CSF formation and 
absorption cannot be the only cause of hydrocephalus because the CSF absorptive capacity 
exceeds that of formation even in patients with severe hydrocephalus (Bergsneider, 2001; 
Johanson et al., 2008). Recently, two theories have emerged to explain the pathology of 
communicating hydrocephalus: the bulk flow theory in which extraventricular obstruction of 
CSF flow occurs and the pulsation theory, which posits that decreased intracranial compliance 
causes ventriculomegaly via increased pulsatile stress on the ventricular walls (Egnor et al., 
2002; Greitz, 2004). 
 
Chapter III 
 
Hydrocephalus: Classification, causes, pathology, treatment and animal models 
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a. Classification 
Congenital vs. acquired. Hydrocephalus can either be congenital, in which the patient is born 
with hydrocephalus, or acquired, where the patient develops hydrocephalus after birth. Both 
congenital and acquired hydrocephalus can be either acute or chronic. In acute hydrocephalus, 
the ventricles are enlarging and intracranial pressure is high or unstable. In contrast, in chronic 
hydrocephalus, the ventricles are enlarged but intracranial pressure is normal or only slightly 
elevated but stable (Bret and Chazal, 1995; Larsson et al., 1999). Both acute and chronic 
hydrocephalus are multifactorial diseases and share a similar pathology; however, chronic 
hydrocephalus progresses more slowly because the adult brain tissue appears to better 
compensate in response to ventricular enlargement than the immature or developing brain 
(Edwards et al., 2004). Congenital hydrocephalus comprises approximately 50% of all cases of 
hydrocephalus and is commonly associated with other genetic diseases, such as spina bifida 
(Schrander-Stumpel and Fryns, 1998; Vintzileos et al., 1983; Zhang et al., 2006). In contrast, 
acquired hydrocephalus develops after birth and is due to brain damage that can be caused by a 
variety of insults, including acute trauma, hemorrhage, stroke, infection or tumors (Jensen and 
Jensen, 1979; Jensen, 1979). However, in both congenital and acquired hydrocephalus, the 
etiology is largely unknown. 
 
Communicating vs. non-communicating. Hydrocephalus can be divided into two broad 
categories: communicating and non-communicating. Non-communicating hydrocephalus results 
from physical obstruction of the ventricular system, which prevents normal CSF flow. A 
common cause of non-communicating hydrocephalus is obstruction of the aqueduct of Sylvius, 
which is the narrowest part of the ventricular system and connects the third and fourth ventricles 
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of the brain. Congenital abnormalities, tumors, genetic defects, meningitis and hemorrhage are 
common sources of obstruction of the ventricular system in non-communicating hydrocephalus 
(Vertinsky and Barnes, 2007). In contrast, in communicating hydrocephalus, the passages of the 
ventricular system remain patent. While the mechanisms leading to communicating 
hydrocephalus remain unclear, excess CSF production by the choroid plexus or abnormal 
reabsorption of CSF by the arachnoid villi has traditionally been thought to be the cause (Egnor 
et al., 2002). However, the development of hydrocephalus due to the overproduction of CSF is 
thought to be extremely rare (McAllister and Chovan, 1998; Mori, 1995).  
Recently, two theories have emerged to explain the pathology of communicating 
hydrocephalus: the bulk flow theory in which extraventricular obstruction of CSF flow occurs 
and the pulsation theory, which posits that decreased intracranial compliance causes 
ventriculomegaly via increased pulsatile stress on the ventricular walls (Egnor et al., 2002; 
Greitz, 2004). In the bulk flow model of communicating hydrocephalus, dilation of all four 
ventricles is thought to be caused by obstruction of CSF distal to the fourth ventricle but 
proximal to the subarachnoid spaces, resulting in an imbalance between CSF formation and 
absorption (Greitz, 2004; Rahme and Bojanowski, 2010). In contrast, the pulsation model is 
based on the idea that nearly all CSF motion is pulsatile, resulting from changes in vascular and 
CSF flow during systole and diastole (Egnor et al., 2002). During presystole, there are no 
pressure gradients in the brain. During early systole, the systolic pulse wave causes a large 
expansion of the arteries with a concomitant and significant decrease of the arterial pulse 
pressure, which is transmitted to the entire subarachnoid space. This arterial expansion causes a 
large volume conduction of CSF that compresses the outlets of the cortical veins and increases 
systolic blood flow in the venous sinus. At the same time, this arterial expansion pushes CSF into 
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the compliant spinal canal. After a brief delay (60 ms), the pulse wave is transmitted to the brain 
capillaries (Greitz, 2004). In contrast, in hydrocephalus, the intracranial capacitance vessels are 
thought to be narrow, resulting in decreased intracranial compliance. During early systole, the 
decreased intracranial compliance restricts arterial expansion, preventing damping of the pulse 
pressure in the arteries.  Due to the decreased volume conduction of the CSF, the systolic CSF 
flow in the dural sinus and in the subarachnoid space is decreased. Thus, due to the decrease in 
arterial expansion, the volume of CSF conduction is also decreased, resulting in increased 
vascular resistance. Subsequently, the high pulse pressure in the arteries is transmitted into the 
brain capillaries, increasing CSF pulse pressure and systolic flow in the aqueduct of Sylvius. 
These changes are thought to result in increased transmantle stress and ventricular dilation 
(Egnor et al., 2002; Greitz, 2004). In sum, the pulsatile model suggests that ventricular dilation is 
caused by the transmission of pulsatile stress through the choroidal arteries and ventricular walls 
due to decreased intracranial compliance, possibly due to scarring in the subarachnoid spaces 
(Egnor et al., 2002; Greitz, 2004; Rahme and Bojanowski, 2010). 
 
Normal pressure hydrocephalus. Normal pressure hydrocephalus (NPH) is a type of chronic, 
communicating hydrocephalus in which ventricular enlargement occurs in the absence of large 
increases in intracranial pressure (Kondziella et al., 2008; Siraj, 2011). Although NPH remains 
underdiagnosed, it is estimated that up to 10% of all dementia patients suffer from NPH (Hakim 
and Adams, 1965; Vale and Miranda, 2002). NPH is characterized by a triad of clinical 
symptoms that include gait ataxia, dementia and urinary incontinence and occurs most 
commonly in patients in their 60s or 70s (Kondziella et al., 2008; Shprecher et al., 2008; Siraj, 
2011). NPH can be either classified as idiopathic, when there is no known cause, or secondary, 
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when there is a clear cause (Kondziella et al., 2008; Siraj, 2011). Secondary NPH can be caused 
by subarachnoid or intraventricular hemorrhage caused by trauma or aneurysms, infections such 
as meningitis and inflammatory conditions (Siraj, 2011). One leading theory for idiopathic NPH 
suggests that poor venous compliance, particularly in the superior sagittal sinus, impairs CSF 
pulsations, which reduces CSF flow through the aqueduct, and CSF absorption through the 
arachnoid villi (Bateman, 2000; Shprecher et al., 2008). Additionally, 83% of patients with 
idiopathic NPH also have hypertension, which may contribute to the disturbances in CSF flow 
found in NPH (Krauss et al., 1996). Cytokines, such as tumor necrosis factor- (TNF) and 
transforming growth factor- (TGF), may also play a role in idiopathic NPH (Li et al., 2007; 
Shprecher et al., 2008; Tarkowski et al., 2003). Both TNF, which is known to regulate CSF 
production, and TGF are elevated in idiopathic NPH (Li et al., 2007; Tarkowski et al., 2003); 
however, it is unclear whether these cytokines accumulate secondary to impaired CSF flow and 
thereby regulate the symptoms of NPH or whether overproduction of these cytokines is an 
adaptive response to hydrocephalus (Shprecher et al., 2008). The placement of shunts to drain 
the excess CSF, as discussed in section IIId, remains the only treatment for NPH (Siraj, 2011). 
 
Hydrocephalus ex vacuo. Hydrocephalus ex vacuo is defined as the enlargement of the ventricles 
due to atrophy of the brain parenchyma (Bradley, 2001; LeMay and Hochberg, 1979). 
Hydrocephalus ex vacuo is commonly present in patients with Alzheimer’s disease and other 
neurodegenerative disorders (LeMay and Hochberg, 1979; Silverberg, 2004). In hydrocephalus 
ex vacuo, the dilation of the ventricular system is often highly asymmetrical, which is in contrast 
to the more symmetrical dilation of the ventricles seen in other types of hydrocephalus, such as 
NPH (Sjaastad et al., 1969). Hydrocephalus is not considered to be related to CSF 
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hydrodynamics, but this conclusion is controversial; it is possible that hydrocephalus ex vacuo 
may be related to the loss of proper CSF flow (Silverberg, 2004). 
 
b. Causes 
Physical malformations. Chiari II and Dandy-Walker malformations as well as aqueductal 
stenosis often lead to hydrocephalus. Chiari II malformations are a prominent cause of 
hydrocephalus, accounting for approximately one-third of infantile hydrocephalus cases 
(Stevenson, 2004; Vertinsky and Barnes, 2007). Chiari II malformations result from failure of 
neural tube closure, and its cardinal signs include myelomeningocele in the thoraco-lumbar 
spine, herniation of the hindbrain into the cervical spinal canal and compression damage to the 
cranial nerves (Shuman, 1995; Stevenson, 2004). Non-communicating hydrocephalus results due 
to impaired CSF outflow from the fourth ventricle (Shuman, 1995; Stevenson, 2004; Vertinsky 
and Barnes, 2007). 
 Dandy-Walker malformations (DWM) are congenital brain malformations that include 
agenesis of the cerebellar vermis, dilation of the fourth ventricle and cyst formation filling the 
posterior cranial fossa, resulting in macrocephaly and hydrocephalus (Pascual-Castroviejo et al., 
1991; Peter and Fieggen, 1999; Vintzileos et al., 1983). Approximately 2.4 to 4% of all 
hydrocephalus cases are caused by DWM (Pascual-Castroviejo et al., 1991). A combination of 
lateral and fourth ventricle shunts is often used to treat hydrocephalus with DWM; left untreated, 
hydrocephalus with DWM is generally fatal within 4 years (Vintzileos et al., 1983). 
 The aqueduct of Sylvius is the narrowest part of the ventricular system, and aqueductal 
stenosis is the most common cause of non-communicating hydrocephalus. Aqueductal stenosis 
can either be primary (congenital) or secondary (acquired) (Vertinsky and Barnes, 2007). 
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Hemorrhage, infection, tumors or ependymal cell loss may all cause aqueductal stenosis, leading 
to enlargement of the lateral and third ventricles (Vertinsky and Barnes, 2007; Wagner et al., 
2003). Often, there is no clear precipitating factor for aqueductal stenosis (Vertinsky and Barnes, 
2007). 
 
Tumors and cysts. Cysts of the posterior cranial fossa resulting from Dandy-Walker 
malformations and arachnoid cysts are common causes of hydrocephalus. Arachnoid cysts are 
fluid collections in the arachnoidal membrane and subarachnoid space and can be either 
congenital or acquired (Pradilla and Jallo, 2007; Vertinsky and Barnes, 2007). Congenital 
arachnoid cysts result from developmental defects and consist of lesions composed of an 
arachnoid membrane that secretes CSF to expand the cyst (Pradilla and Jallo, 2007; Vertinsky 
and Barnes, 2007). These cysts likely result from alterations in CSF flow (Pradilla and Jallo, 
2007). In contrast, acquired arachnoid cysts are caused by trauma, such as hemorrhage, and are 
associated with arachnoid scarring (Pradilla and Jallo, 2007; Vertinsky and Barnes, 2007). 
Although most cysts remain stable, the enlargement of cysts, often due to active CSF secretion 
from the cyst membrane, leading to elevated ICP, hypertension and hydrocephalus (di Rocco et 
al., 1981; Pradilla and Jallo, 2007). 
 Neoplasms occurring with in the first two years of life are rare and include astrocytomas, 
embryonic tumors and mesenchymal neoplasms (Vertinsky and Barnes, 2007). These tumors 
often occur along the midline of the ventricular pathways, resulting in elevated ICP and 
hydrocephalus (Vertinsky and Barnes, 2007). Choroid plexus tumors are the most common 
intraventricular tumors in children and arise from the epithelial cells of the choroid plexus. 
Because the choroid plexus is the primary producer of CSF, choroid plexus tumors often cause 
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hydrocephalus due to CSF overproduction (Coates et al., 1989; Vertinsky and Barnes, 2007). If 
the tumor becomes large enough, it can also cause obstructive hydrocephalus (Coates et al., 
1989; Vertinsky and Barnes, 2007). Unfortunately, the high vascularity of these tumors often 
makes complete removal impossible, and shunts are often required (Kumar and Singh, 2005; 
Nagib and O'Fallon, 2000). Posterior fossa and third ventricular tumors also often lead to 
hydrocephalus. Posterior fossa tumors cause non-communicating hydrocephalus by obstructing 
CSF flow at or below the level of the aqueduct and fourth ventricle (Vertinsky and Barnes, 2007; 
Zimmerman et al., 1992). Similarly, third ventricle tumors cause non-communicating 
hydrocephalus by blocking CSF flow at the foramen of Monroe, body of the third ventricle or 
cerebral aqueduct (Ambrosino et al., 1988; Vertinsky and Barnes, 2007). 
 
Ependymal cell denudation. Although ependymal cell loss is generally considered to result from 
enlargement of the ventricles and stretching of the ependymal lining (Bannister and Mundy, 
1979; Bruni et al., 1985; Del Bigio, 1993; Sarnat, 1995), some studies suggest that ependymal 
cell denudation may be a causative factor in hydrocephalus (Jimenez et al., 2001; Wagner et al., 
2003). In the hyh mouse model of hydrocephalus, the ependymal lining of the aqueduct of 
Sylvius denudes during embryonic and early postnatal life (Jimenez et al., 2001; Wagner et al., 
2003). Subsequently, the aqueduct becomes stenosed (Wagner et al., 2003). It is possible that the 
negatively charged glycocalyx rich in sialic residues present on the surface of the ependyma 
creates a repellant effect, maintaining aqueductal patency. When the ependyma denude, these 
negatively charged residues are lost, resulting in aqueductal stenosis (Wagner et al., 2003). In 
support of this hypothesis, the aqueduct was never found to be obliterated in hyh mice where the 
ependyma remained intact (Wagner et al., 2003). However, evidence showing ependymal loss 
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prior to hydrocephalus in humans is limited (Dominguez-Pinos et al., 2005); thus, whether 
ependymal denudation is a causative factor in human hydrocephalus is unknown. 
 
Loss of cilia function. Several studies suggest that impaired CSF flow caused by defective 
ependymal cilia results in hydrocephalus in both humans and animals (al-Shroof et al., 2001; 
Banizs et al., 2005; Bush, 2000; Davy and Robinson, 2003; Dawe et al., 2007; De Santi et al., 
1990; Ibanez-Tallon et al., 2004; Picco et al., 1993). Many studies have shown that humans with 
immotile cilia or ciliary dyskinesia develop hydrocephalus (al-Shroof et al., 2001; Bush, 2000; 
De Santi et al., 1990; Picco et al., 1993). Multiple models of hydrocephalus have also been 
developed based on ciliary defects. Transgenic mice with ciliary defects either show defective 
CSF reabsorption (hy3 mice) (Davy and Robinson, 2003; Dawe et al., 2007), excessive CSF 
production (Tg737orpk mice) (Banizs et al., 2005) or non-communicating hydrocephalus caused 
by a loss of directional CSF flow leading to aqueductal stenosis (Mdnah5 mice) (Ibanez-Tallon 
et al., 2004). Thus, although there is a clear link between ciliary dysfunction and hydrocephalus, 
it remains unclear how ciliary defects cause hydrocephalus in humans. 
 
Infection and dysregulation of cytokines. Hydrocephalus may also be caused by infection or 
dysregulation of cytokines. In infants, prenatal or postnatal infections are a common cause of 
hydrocephalus. Prenatal infections can be caused by bacterial or herpes infections traveling from 
the cervix to the amniotic fluid or by toxoplasmosis, rubella, cytomegalovirus (CMV) or herpes 
simplex infections traveling through the placenta (Vertinsky and Barnes, 2007). Of these 
infections, CMV is the most common cause of hydrocephalus. Hydrocephalus can also from 
meningeal or ependymal reactions leading to aqueductal stenosis (Becker, 1992; Boesch et al., 
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1989; Vertinsky and Barnes, 2007). Meningitis is one of the most common infections that leads 
to hydrocephalus postnatally and can be caused by bacterial, viral, fungal or parasitic infections. 
Meningitis causes hydrocephalus due to inflammation of the arachnoid granulations and 
decreased absorption of CSF. Additionally, inflammatory and blood products can lead to 
arachnoiditis (Bell, 1992; Vertinsky and Barnes, 2007).  
 Dysregulation of cytokines has also been implicated in the pathogenesis of 
hydrocephalus. Altered concentrations of cytokines are found in the CSF in many animal models 
of hydrocephalus, including the H-Tx rat, and have been shown to affect normal cortical 
development (Owen-Lynch et al., 2003; Vetsika et al., 1999). Concentrations of transforming 
growth factor 1 and 2 (TGF-1 and TGF-2) have also been shown to be elevated in the CSF 
of adults and infants with ventricular dilation caused by intracerebroventricular hemorrhage 
(Flood et al., 2001; Whitelaw et al., 1999). In stronger support of a causative role of cytokines in 
the pathogenesis of hydrocephalus, injecting TGF- into the subarachnoid space in mice and 
ventricular infusions of fibroblast growth factor 2 (FGF-2) in rats resulted in ventriculomegaly 
and communicating hydrocephalus (Johanson et al., 1999; Tada et al., 1994). Hydrocephalus in 
these animals was characterized by ventriculomegaly, elevated ICP, reduced CSF production and 
collagen deposits in the arachnoid villi (Hakvoort and Johanson, 2000; Johanson et al., 1999; 
Tada et al., 1994). Further, overexpression of TGF-1 in GFAP-positive cells in mice resulted in 
communicating hydrocephalus with severe motor incoordination (Galbreath et al., 1995; Wyss-
Coray et al., 1995). Whether TGF- or FGF-2 plays a causative role in human hydrocephalus has 
yet to be determined. 
 
 
Hemorrhage. Germinal matrix (GM) or intraventricular hemorrhage (IVH) occurs in 20% of 
premature infants and often results in hydrocephalus (Kazan et al., 2005; Vertinsky and Barnes, 
2007). Hemorrhage in preterm infants results from the rich blood supply of the subependymal 
germinal matrix, which lacks astrocytic support, and fluctuations in intravascular pressures 
(Cherian et al., 2004). Fifteen percent of infants with IVH develop ventricular enlargement that 
requires shunt insertion; however, these infants have a high frequency of neurodevelopmental 
disabilities, including motor dysfunction and cognitive impairment (Cherian et al., 2004; Davis 
et al., 1987; Murphy et al., 2002). Hemorrhage results in hydrocephalus due to obstruction of the 
ventricular system or arachnoid villi by red blood cells and subsequent obliterative, fibrosing 
arachnoiditis, impairing CSF absorption (Cherian et al., 2004; Vertinsky and Barnes, 2007). 
Meningeal fibrosis and subependymal gliosis may also occur, obstructing CSF outflow from the 
foramina of the fourth ventricle and the aqueduct of Sylvius (Cherian et al., 2004; Hill et al., 
1984; Larroche, 1972). 
 
Hypertension. Venous hypertension can increase pressure within the dural sinuses, creating a 
decreased pressure gradient across the arachnoid villi, leading to decreased CSF absorption 
(Hayward, 2005; Vertinsky and Barnes, 2007). This most often results in hydrocephalus in 
patients younger than 18 months because the open sutures and soft, undermyelinated and 
immature white matter allow ventricular expansion without resistance (Hayward, 2005; 
Vertinsky and Barnes, 2007). In older patients in whom the skull is not capable of expanding, 
venous hypertension creates a pseudo-tumor-like state (Hayward, 2005; Karahalios et al., 1996). 
Venous hypertension may be caused by developmental conditions, such as malformations of the 
skull base restricting venous outflow, congenital heart disease, pulmonary disease with elevated 
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central venous pressure or thrombosis of central veins or sinuses caused by infection, vascular 
malformation or coagulopathy (Vertinsky and Barnes, 2007). Hydrocephalus caused by venous 
hypertension is often treated with shunt surgery to drain the excess CSF caused by reduced 
absorption (Hayward, 2005). 
 
Aging. Changes in the CNS caused by aging have also been shown to contribute to 
hydrocephalus. In particular, normal pressure hydrocephalus is common in elderly patients and is 
often comorbid with Alzheimer’s disease (Long, 1985; Silverberg et al., 2003). With normal 
aging, the choroid plexus epithelial layer becomes flattened and calcified, reducing CSF 
production (May et al., 1990; Preston, 2001; Silverberg et al., 2002). The production and 
secretion of CSF by the choroid plexus is also regulated by vasopressin, and elevations in 
vasopressin concentrations in aging lead to decreased CSF production (Faraci et al., 1990; 
Frolkis et al., 1999). Additionally, CSF absorption decreases due to thickening of the arachnoid 
villi and reduced drainage into the vascular system, resulting in the build-up of toxic products, 
such as amyloid beta, in the CSF (Albeck et al., 1998; Bech et al., 1997; Bellur et al., 1980). 
Increases in venous pressure may also reduce CSF absorption (Rubenstein, 1998). Reduced CSF 
turnover and increased CSF volume also occurs with age, likely due to tissue atrophy, further 
contributing to the build-up of toxic substances in the CSF and possibly leading to 
ventriculomegaly (Foundas et al., 1998; Matsumae et al., 1996; Wahlund et al., 1996). Age-
related decline in the protective, antioxidant enzymes of the choroid plexus and other brain 
tissues also contributes to oxidative stress and DNA damage these tissues (Preston, 2001). 
Although all of these processes are common to normal aging, they may make certain individuals 
more susceptible to hydrocephalus.  
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Genetic mutations. Mutations in the L1 neural adhesion molecule, located on near the telomere 
of the long arm of the X chromosome in Xq28, are the only known genetic cause of 
hydrocephalus in humans (Fransen et al., 1995; Zhang et al., 2006). Deficiencies in this protein 
result in CRASH syndrome, characterized by corpus callosum hypoplasia, mental retardation, 
adducted thumbs, spastic paraplegia and hydrocephalus (Fransen et al., 1995; Yamasaki et al., 
1997). The severity of the disease is strongly correlated to the type of mutation in the L1CAM 
gene, with mutations that produce truncations in the extracellular domain of the L1 protein being 
more likely to produce severe hydrocephalus with mental retardation and early death (Yamasaki 
et al., 1997). L1CAM normally plays a key role in axon outgrowth and pathfinding as well as 
synaptic plasticity; however, how mutations in L1CAM lead to hydrocephalus remain unclear 
(Panicker et al., 2003; Rolf et al., 2001; Sztriha et al., 2000). Some studies suggest that L1-
related hydrocephalus develops ex vacuo due to increased degeneration of neural cell types due 
to disturbed interactions between cells and between cells and the extracellular matrix (Dahme et 
al., 1997; Rolf et al., 2001). It is also possible that severe brain malformations resulting from 
altered development produce aqueductal stenosis and hydrocephalus (Rolf et al., 2001). 
  
c. Pathology 
The ventriculomegaly and elevated intracranial pressure that accompany hydrocephalus result in 
a wide variety of pathological changes. Although hydrocephalus is a multifactorial disease, the 
pathological changes observed in human and animal models of hydrocephalus are fairly 
consistent and include ependymal and subependymal changes, changes to the choroid plexus and 
altered CSF flow, vascular changes, edema, white matter loss, cell death and disorganization and 
gliosis. 
 
Ependymal and subependymal changes. As the ventricles enlarge, the ependymal layer stretches 
and is eventually destroyed, especially over white matter; the degree of ependymal damage is 
dependent on the severity and rate of ventricular expansion (Bannister and Mundy, 1979; Del 
Bigio, 1993; Sarnat, 1995). Slowly enlarging lateral ventricles are less likely to lose their 
ependymal lining; instead, ventricular enlargement causes the cuboidal and columnar ependymal 
cells to flatten and increase their surface area (Del Bigio, 1993; Page et al., 1979). Additionally, 
as ependymal cells stretch and are lost, the cilia and microvilli that line the ventricles are also 
lost, especially over the roof and dorsolateral angle of the lateral ventricles (Page, 1975; 
Raimondi et al., 1976). Macrophages then appear on the surface of the ventricular walls to 
remove the debris (Del Bigio, 1993; Go et al., 1976). Because ependymal cells do not proliferate 
(Spassky et al., 2005), reactive astrocytes form a barrier that separates the periventricular tissue 
from the CSF (Del Bigio, 1993; Takano and Becker, 1997). Additionally, the subventricular 
zone, which lies immediately beneath the ependymal cells around the lateral ventricles, becomes 
disorganized and shows a marked reduction of proliferative cells (Dominguez-Pinos et al., 2005; 
Jimenez et al., 2009). Neuroblasts become displaced to the ventricular surface and show reduced 
migration through the rostral migratory stream to the olfactory bulb (Dominguez-Pinos et al., 
2005; Jimenez et al., 2009). These changes in the SVZ have been suggested to be caused by the 
aberrant expression of trophic factors (Del Bigio, 2004; Fukumitsu et al., 2000; Miyan et al., 
2001). 
 
Changes in CSF and the choroid plexus. Morphological and physiological changes to the choroid 
plexus include epithelial cell atrophy and cytological changes, which may reflect reduced 
secretory activity (Preston et al., 2003; Silverberg et al., 2002). Additional changes observed in 
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experimental models of hydrocephalus include distortion of CP microvilli, cell flattening and 
vacuolization and enlargement of intracellular spaces (Del Bigio, 2001; Dohrmann, 1971; Go et 
al., 1976; Lawson and Raimondi, 1973).  
 Reduced outflow of CSF is also common in hydrocephalus, causing CSF to accumulate 
in the ventricles and subarachnoid spaces (Del Bigio, 1993). Because normal CSF flow is 
important for distributing growth factors, signaling molecules and neurotransmitters throughout 
the brain and for clearing waste products from the brain, reduced CSF outflow impairs neuronal 
function (Bergsneider, 2001; Di Terlizzi and Platt, 2006; Johanson, 2003; Podell and 
Hadjiconstantinou, 1997; Vaughn et al., 1988). Because shunting does not restore normal CSF 
flow, neurological deficits caused by impaired CSF flow often persist even after shunting 
(Mashayekhi et al., 2002; McAllister and Chovan, 1998). 
 
Vascular changes. Reductions in blood flow, especially in white matter, have been demonstrated 
in humans with hydrocephalus using Doppler blood flow, PET, SPECT, MRI and CT (Goh and 
Minns, 1995; Nakano et al., 1996; Shih and Tasdemiroglu, 1995). Reductions in blood flow are 
correlated with lateral ventricle size in infants (Hill and Volpe, 1982; Lui et al., 1990). A 
reduction in the quantity and caliber of capillaries has also been shown, resulting in ischemia and 
injury to oligodendrocytes and axons (Del Bigio, 1993; Klinge et al., 2003).  This reduction in 
capillaries is thought to be due to a combination of increased ICP and distortion of the brain 
parenchyma (DE, 1950; Del Bigio and Bruni, 1988; Di Rocco et al., 1979). Interestingly, in the 
periventricular white matter of hydrocephalic animals, separations of endothelial tight junctions 
have been observed, suggesting an alternate pathway for CSF absorption in hydrocephalus 
(Nakada et al., 1992; Nakagawa et al., 1984; Nakagawa et al., 1985; Okuyama et al., 1987). 
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Tight junctions may therefore represent dynamic structures that allow the paracellular movement 
of substances across the blood-brain barrier and may contribute to molecular transfer under 
pathological conditions (Bundgaard, 1986; Madara, 1988). 
 
Periventricular edema. Elevated ICP is accompanied by edema in the periventricular region 
(Drake et al., 1989; Hiratsuka et al., 1982; Murata et al., 1981). Comparisons of wet and dry 
tissue weights and specific gravity analyses have shown that tissue water content is increased 
above control values in the periventricular region in hydrocephalic animals, and histological 
analyses have shown increased extracellular spaces in the white matter surrounding the ventricles 
in humans (Di Rocco et al., 1977; Fishman and Greer, 1963; Higashi et al., 1986; Takei et al., 
1987). This periventricular fluid likely represents stagnant extracellular fluid (Del Bigio, 1993). 
Edema and changes in the extracellular spaces may have severe consequences for neuronal 
function. Maintenance normal volume and tortuosity of the extracellular spaces is necessary for 
the movement of neurotransmitter and their metabolites and waste products from energy 
metabolism (Del Bigio, 1993; Moseley et al., 1990; Nicholson, 1988). Therefore, compression or 
impeded flow of extracellular fluid through the extracellular spaces can upset the homeostasis of 
the local microenvironment and disrupt normal neuronal function (Del Bigio, 1993).  
 
White matter loss. Myelin loss and axonal damage are important neuropathological changes in 
hydrocephalus, and measurements of myelin basic protein (MBP) in the CSF of hydrocephalic 
humans have been used to determine the severity of brain damage (Del Bigio, 2004; Sutton et al., 
1983). Atrophy of periventricular white matter, including the corpus callosum, and damage to 
periventricular axons are frequently found in humans and animal models of hydrocephalus (Del 
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Bigio and Zhang, 1998; Del Bigio, 2001; Gadsdon et al., 1979). Atrophy of the fimbria/fornix 
connections between the hippocampus and forebrain are common in hydrocephalus in animals 
and humans, resulting in cognitive changes and memory dysfunction in severe hydrocephalus 
(Del Bigio et al., 2003). Oligodendrocytes also appear to be directly damaged by hydrocephalus 
and can be seen in the white matter of hydrocephalic rats and cats, resulting in white matter 
hypomyelination (Del Bigio et al., 1994; Del Bigio and Zhang, 1998; Hanlo et al., 1997). Edema 
in the periventricular white matter has been suggested as a primary cause of myelin damage 
(Feigin, 1983; Weller et al., 1971). 
 
Neuronal damage and cell death and disorganization. Severe hydrocephalus results in 
considerable loss of brain tissue, including thinning of the cortex, redundant cortical gyri and 
gross atrophy of the basal ganglia (Clark and Milhorat, 1970; DE, 1950; Del Bigio, 1993; Di 
Rocco et al., 1977). In the basal ganglia, hydrocephalus produces functional injuries of 
cholinergic, dopaminergic and GABAergic neurons due to mechanical distortion (Tashiro et al., 
1997b). Similarly, in the cerebral cortex and hippocampus, the loss of nonpyramidal interneurons 
without overt changes in neuronal architecture suggests a functional impairment of these 
neuronal systems in the pathogenesis of hydrocephalus prior to gross morphological changes 
(Tashiro et al., 1997a). Shrunken, dark neurons and cytoplasmic vacuolization have also been 
found in hydrocephalic cats (Hale et al., 1992; Wright et al., 1990). Neuronal pyknosis, 
vacuolization and degeneration have all been demonstrated in hydrocephalic humans (Del Bigio, 
1993; Glees and Voth, 1988). Pathological changes in neurons are likely secondary to myelin 
loss and axonal damage (Del Bigio, 2004). Reduction in the quantity of dendritic spines and 
branches and reduced synaptic contacts have also been demonstrated (Del Bigio and Zhang, 
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1998; Harris et al., 1997; McAllister et al., 1985). In the developing rat brain, cortical 
compression and reduced cell density have been detected in severe hydrocephalus, although 
there were no changes in total cell number (Jones et al., 1991). 
 
Glial changes. Subependymal astrogliosis is commonly observed in humans and animals with 
chronic hydrocephalus; however, astrogliosis has only been demonstrated in cases of severe 
hydrocephalus (Bruni et al., 1985; Del Bigio, 1993; Yoshida et al., 1990). Additionally, 
following ependymal denudation, astrocytes have been shown to proliferate and form a 
superficial cell layer to replace the lost ependyma (Paez et al., 2007; Sarnat, 1995). Astrocyte 
metabolism has also been shown to be disturbed relatively early in the kaolin-model of 
hydrocephalus in rats, and these disturbances persist throughout the chronic phase of 
hydrocephalus and are not resolved upon shunting, contributing to the neurological deficits that 
persist after shunting (Kondziella et al., 2003; Kondziella et al., 2008). Alterations in aquaporin 4 
channel expression on astrocytes and ependymal cells have also been shown to affect 
hydrocephalus. Upregulation of aquaporin 4 is associated with brain edema, and aquaporin 4 
knock-out mice have reduced edema (Owler et al., 2010; Papadopoulos and Verkman, 2007; 
Verkman et al., 2006). However, aquaporin 4 knock-out mice have worse clinical outcomes in 
hydrocephalus, likely due to the role of astrocytes in glia limitans in removing the redundant 
water from the parenchyma to the subarachnoid space (Verkman et al., 2006). 
 Microglia also become reactive throughout the brain during the intermediate stages of 
hydrocephalus in H-Tx rats, and reactive microglia have been demonstrated in the periventricular 
region and basal ganglia of human fetal hydrocephalus (Mangano et al., 1998; Ulfig et al., 2004). 
With increasing severity of human fetal hydrocephalus, the microglial activation spreads from 
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the periventricular region throughout the rest of the brain (Ulfig et al., 2004). Additionally, 
activated phagocytic macrophages have been found on the ependymal ventricular lining in 
human hydrocephalus, and likely act to remove detached ependymal cells (Del Bigio, 1993; 
Ulfig et al., 2004). However, both reactive astrogliosis and microgliosis were shown to be 
reduced following shunting in an experimental model of hydrocephalus, suggesting that these 
changes are, at least in part, reversible (Miller and McAllister, 2007). 
 
d. Diagnosis and treatment 
Diagnosis. Macrocephaly and increased intracranial pressure (ICP) are common symptoms of 
hydrocephalus (Vertinsky and Barnes, 2007). Macrocephaly is defined as a head circumference 
more than two standard deviations above the mean and is often associated with developmental 
delays, seizures, a neurocutaneous syndrome and elevated venous pressure (Vertinsky and 
Barnes, 2007). Symptoms of elevated ICP depend on age and include macrocephaly, bulging 
fontanelles, split sutures, reduced eating, vomiting, irritability, vision impairment, headache, 
lethargy, stupor, encephalopathy, sixth nerve palsy and papilledema (Vertinsky and Barnes, 
2007). When hydrocephalus develops later in life, macrocephaly does not occur due to the 
hardening of the skull; however, symptoms of elevated ICP are still present and can be used for 
diagnosis. Normal pressure hydrocephalus is characterized by gait and cognitive impairments 
and urinary incontinence (Shprecher et al., 2008; Siraj, 2011).  
 Diagnosis of hydrocephalus is confirmed using imaging through ultrasonography (US), 
computed tomography (CT) and/or magnetic resonance imaging (MRI). Ventricular enlargement 
in the absence of atrophy or underdevelopment detected by these tests is indicative of 
hydrocephalus (Vertinsky and Barnes, 2007). Enlargement of the anterior and posterior recesses 
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of the third ventricle, rounded configuration of the lateral ventricles, increased flow voids on the 
MRI and dilation of the temporal horns are also suggestive of hydrocephalus (Gammal et al., 
1987; Vertinsky and Barnes, 2007). Periventricular edema, which is common in patients with 
hydrocephalus, can also be detected as blurred or ill-defined ventricular margins (Vertinsky and 
Barnes, 2007). 
 US or CT is initially used to diagnose hydrocephalus in the fetus and infant because they 
are more practical than MRI in these cases. Because it is a noninvasive and repeatable bedside 
procedure, doppler US is used to identify infants with enlarged ventricles and elevated ICP and 
to determine whether shunting is required (Hoon and Melhem, 2000; Vertinsky and Barnes, 
2007). US provides a good assessment of brain structure and maturation and is therefore good at 
detecting abnormalities in the periventricular white matter (Hoon and Melhem, 2000). However, 
US lacks specificity and sensitivity and does not show subtle lesions in the brainstem or 
cerebellum (Hoon and Melhem, 2000; Kuban, 1998; Paneth, 1999). Similarly, CT scans are 
practical because they are less costly than MRIs and often do not require sedation (Hoon and 
Melhem, 2000). Additionally, CT scans can detect enlarged ventricles and are often used to 
determine whether surgery is required (Gammal et al., 1987; Hoon and Melhem, 2000; Vertinsky 
and Barnes, 2007). However, CT provides incomplete information in diagnosing small or 
isodense pathological changes in the aqueduct and foramen of Monroe (Gammal et al., 1987). As 
such, the use of MRI is often necessary to visualize small obstructions in midline structures 
(Gammal et al., 1987). 
Because of its superior contrast resolution, multiplanar imaging capability, lack of bone 
artifacts, absence of ionizing radiation and the ability to assess CSF flow and tissue anisotrophy, 
MRI is the preferred imaging method for determining anatomical changes present and the type of 
 
surgery required in patients with hydrocephalus (Hoon and Melhem, 2000; Vertinsky and 
Barnes, 2007). The information provided by MRI with respect to CSF flow is helpful in 
assessing complex, compartmentalized or encysted hydrocephalus (Gammal et al., 1987; 
Vertinsky and Barnes, 2007). MRI can also be used to visualize small obstructions in the 
ventricular system, which cannot be seen via CT, and to determine whether a cyst or tumor is 
present and blocking the ventricular system (Gammal et al., 1987; Vertinsky and Barnes, 2007). 
However, MRIs are more expensive and require sedation (Hoon and Melhem, 2000). 
 
Shunts. Untreated hydrocephalus results in severe brain damage and has a high mortality rate of 
50 – 96%; thus, treatment is required to prevent further brain damage and death (Laurence and 
Coats, 1962; Yashon, 1963). Treating hydrocephalus by redirecting CSF flow through the 
insertion of a shunt into the ventricular system was developed over fifty years ago by Nulsen and 
Spitz and remains the primary treatment for hydrocephalus today (Beni-Adani et al., 2006; 
Nulsen and Spitz, 1951). Although the original shunt diverted excess CSF into the jugular vein, 
today shunts drain excess CSF into the abdominal cavity, lungs or heart and use adjustable 
valves to tailor the drainage rate among patients (Del Bigio, 2004; Zemack and Romner, 2002). 
Shunt surgery is now primarily used for patients with communicating hydrocephalus or in non-
communicating hydrocephalus in which absorptive problems are also present, whereas 
endoscopic third ventriculostomy (ETV, discussed in more detail below) is gaining acceptance as 
the preferred treatment for non-communicating hydrocephalus (Beni-Adani et al., 2006). 
However, as it is difficult to rule out an additional absorptive problem in patients with non-
communicating hydrocephalus, ETV is less frequently used (Beni-Adani et al., 2006).  
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The placement of shunts greatly improves survival and outcomes of patients with 
hydrocephalus; however, early shunt surgery is necessary to prevent severe, irreversible effects, 
such as severe motor disabilities, epilepsy and intellectual impairment (Del Bigio et al., 1997; 
Takei and Sato, 1995; Tashiro and Drake, 1998). In children with shunted hydrocephalus, 
shunting restores myelination loss and changes in brain weight and size (Del Bigio, 2004; 
Gadsdon et al., 1979). Additionally, shunting has been shown to reduce the size of the ventricles, 
promote reexpansion of the cortical mantle and reduce edema of the periventricular tissues (Hale 
et al., 1992). Shunting of geriatric patients with normal pressure hydrocephalus has also been 
shown to improve memory, gait and urinary incontinence and reduce bradykinesia and 
Parkinson-like symptoms (Goodman and Meyer, 2001). Animal models have also suggested that 
cerebral blood flow and glucose utilization are restored, behavior and memory improve, myelin 
deposition improves, mild axonal damage is reversed and partial restoration of neurotransmitters 
occurs (Del Bigio et al., 1997; Del Bigio, 2004; Hale et al., 1992; Hawkins et al., 1997; Tashiro 
and Drake, 1998). However, not all pathological changes caused by hydrocephalus can be 
restored by shunting. Ventricles often remain enlarged, the ependymal lining is not restored, 
capillaries do not resume their normal configuration, severed axons cannot be restored and 
reactive astrogliosis causes persistent periventricular changes (Del Bigio, 1993; Del Bigio, 2001; 
Del Bigio, 2004; Takei and Sato, 1995) 
Although shunts have greatly improved patient survival and outcomes, they have a high 
failure rate. Forty percent of shunts fail within the first year, and two-thirds of shunts fail within 
10 years after surgery (Drake et al., 2000; Patwardhan and Nanda, 2005). Infection, obstruction 
of the shunt, overdrainage, slit ventricle syndrome, craniosynostosis and low cranial-brain 
compliance are all causes of shunt failure (Beni-Adani et al., 2006). The reported incidence of 
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shunt infections ranges from 2 to 39% and includes infections from Staphylococcus epidermidis 
and S. aureus (Turgut et al., 2005). In cases of infection, the infected shunt must be removed and 
replaced with a new shunt following a course of system antibiotics (Turgut et al., 2005). The 
high replacement rate of shunts, estimated to be between 1.6 and 3.6 revisions per patient, results 
in children receiving multiple neurosurgeries throughout their lives (Lazareff et al., 1998). 
Improvements made to shunt surgery have also not been without complications, such as cor 
pulmonale and shunt nephritis due to cardiac shunting, bowel erosion from spring-coiled 
catheters, obstruction of anti-siphon devices and tonsillar herniation due to lumboperitoneal 
shunts (Drake et al., 2000). As a result, further shunt improvements and new therapeutics are 
necessary to improve treatment of hydrocephalus. 
 
Endoscopic third ventriculostomy. Endoscopic third ventriculostomy (ETV) is a relatively new 
endoscopic procedure used for patients with an obstruction at or distal to the posterior of the 
third ventricle who have patent subarachnoid spaces (Vertinsky and Barnes, 2007). To bypass 
this obstruction, a surgical opening is made in the floor of the third ventricle, restoring CSF flow 
(Vertinsky and Barnes, 2007). ETV is primarily used in patients older than two years with a 
well-defined anatomical obstruction, however, moderate success has been achieved in infants 
with posthemorrhagic or postinfectious HC as well as those with Chiari II malformations 
(Vertinsky and Barnes, 2007). ETV is successful and avoids the complications and need for 
repeat surgeries common with shunt placement. Additionally, there is no risk of overdrainage 
and a low risk of infection. However, the failure rate of ETV in infants ranges from 30 – 90% 
(Beni-Adani et al., 2006). This high failure rate is thought to be the result of the age of the 
patient, the underlying pathology (i.e., ETV did not eliminate the need for shunt placement) and 
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uncontrolled intraoperative bleeding (Beni-Adani et al., 2006). Additionally, in contrast to shunt 
placement, ventricular size decreases more slowly and to a lesser degree (Vertinsky and Barnes, 
2007). Thus, better classification of hydrocephalus is necessary to determine whether a patient 
would benefit from ETV (Beni-Adani et al., 2006). 
 
Pharmacological treatments. Although a variety of pharmacological agents have been 
administered to hydrocephalic patients for centuries, no current drug treatments exist (Del Bigio, 
2004). Most treatments in the past half century have focused on reducing CSF production (Del 
Bigio, 2004). Although the carbonic anhydrase inhibitor acetazolamide reduced CSF production 
by 60%, it produced no clinical improvement in patients with hydrocephalus (ELVIDGE et al., 
1957). Likewise, furosemide, a diuretic that inhibits sodium reabsorption in the renal tubules and 
is capable of affecting fluid balances in the brain showed no benefit in children with post-
hemorrhagic hydrocephalus (Shinnar et al., 1985). The hyperosmolar agent isosorbide has been 
suggested as a treatment for hydrocephalus but lacked efficacy in clinical trials and has therefore 
not been tested in a randomized controlled trial (Lorber, 1975; Lorber et al., 1983). Further, the 
Na+-K+-ATPase pump ouabain has not been tested in clinical trials due to toxicity (Del Bigio, 
2004). It is likely that drugs that attempt to reduce CSF production are ineffective because CSF 
plays an important role in flushing waste products into the blood, and reducing CSF production 
would not aid in cases of hydrocephalus where CSF flow or absorption is blocked because the 
pulse waves that cause ventricular enlargement would persist (Del Bigio, 2004).  
 Treatments that attempt to reopen obstructed CSF pathways have also been attempted. 
However, intrathecal injections of hyaluronidase in children with post-tuberculosis 
hydrocephalus had little effect (Schoeman et al., 1991). Additionally, urokinase and 
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streptokinase, which are fibrinolytic enzymes, were infused into the ventricular CSF following 
intraventricular hemorrhage to disperse blood clots and prevent scarring; however, these drugs 
also showed limited improvement (Hansen et al., 1997; Yapicioglu et al., 2003). Anti-
inflammatory drugs have also been attempted in cases of hemorrhagic hydrocephalus with little 
improvement in preventing or treating hydrocephalus (Erler and Klaber, 2001; Wilkinson et al., 
1974).  
 A number of treatments have also been attempted to prevent the brain damage that 
accompanies hydrocephalus; however, these treatments have only been attempted in animal 
models of hydrocephalus. Nonetheless, nimodipine, which blocks L-type calcium channels, and 
magnesium sulfate, which blocks NMDA receptors and voltage- and receptor-operated calcium 
channels, have shown behavioral and structural protection in the kaolin model of hydrocephalus 
(Del Bigio and Massicotte, 2001; Khan et al., 2003a; Khan et al., 2007). These protective effects 
are likely due to their effect on smooth muscle cell calcium channels and improved cerebral 
blood flow (Del Bigio and Massicotte, 2001; Khan et al., 2003a). In contrast, sodium channel 
blockers, such as mexiletine and riluzole, calcineurin inhibitors, such as tacrolimus and 
cyclosporine, and calpain inhibitor 1 showed no benefits in animal models of hydrocephalus (Del 
Bigio et al., 2002; Khan et al., 2003b). Further studies are necessary to confirm neuroprotective 
drug effects in humans to determine their benefit in the treatment of hydrocephalus. 
 
e. Experimental models of hydrocephalus 
Induced models. There are currently a number of animal models being used to gain insight into 
the pathophysiology of hydrocephalus. The first models of hydrocephalus were developed by 
inserting or injecting substances in the ventricular systems of various animals. The first model of 
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hydrocephalus involved inserting a cotton plug into the aqueduct dogs to mimic non-
communicating hydrocephalus (Dandy, 1919). Since then, a number of other substances have 
been injected into the ventricular system to cause hydrocephalus. A commonly used inducible 
model of hydrocephalus involves injecting kaolin (aluminum silicate) into the cisterna magna of 
the rodent brain. This causes a strong inflammatory response in the meninges that results in 
obstruction of the outlets of the fourth ventricle and ventricular enlargement as a result of 
inflammatory scarring (da Silva Lopes et al., 2009). Injection of silicone oil into the cisterna 
magna also results in hydrocephalus due to mechanical obstruction of CSF flow out of the fourth 
ventricle, resulting in increased intracranial pressure and ventricular dilation (Del Bigio and 
Bruni, 1991). Injection of neuraminidase from Clostridium perfingens into the lateral ventricle of 
rats resulted in the death and detachment of ependymal cells from the lateral ventricles, third 
ventricle, cerebral aqueduct and the rostral half of the fourth ventricle, resulting in aqueductal 
stenosis (Grondona et al., 1996). Ventriculomegaly of the lateral and third ventricles also 
occurred (Grondona et al., 1996). These pathological changes were thought to be the result of 
cleavage of sialic acid residues from the ependymal surface glycoproteins and glycolipids 
(Grondona et al., 1996). Recently, a model of acute obstructive hydrocephalus was developed in 
rats using N-butyl cyanoacrylate (NBCA). Injection of NBCA into the fourth ventricle produced 
hydrocephalus in 73.3% of rats without diffuse inflammation (Park et al., 2011). However, the 
onset of hydrocephalus in these mice was rapid and there was a high mortality rate due to severe 
brain swelling and brain stem compression (Park et al., 2011). In all of these models, 
hydrocephalus is often accompanied by an inflammatory response or a physical tissue distortion 
that is not present in most cases of human hydrocephalus. As a result, it is difficult to determine 
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the specific cellular changes caused by hydrocephalus, and their relevance to human 
hydrocephalus is unclear. 
 
Genetic models. The first congenital models of hydrocephalus were developed through 
spontaneous mutations in rats; namely, the hydrocephalic Texas strain (H-Tx) and the LEW/Jms 
strain. However, the penetrance in both of these models is low, at approximately 40% in the H-
Tx rats and 28% in the LEW/Jms strain (Jones et al., 2000b). While the LEW/Jms strain presents 
with aqueductal stenosis and therefore represents a model of non-communicating hydrocephalus, 
it remains controversial whether the H-Tx model displays communicating or non-communicating 
hydrocephalus. Studies have demonstrated stenosis of the aqueduct of Sylvius in H-Tx rats 
(Boillat et al., 1999; Jones and Bucknall, 1988); however, hydrocephalus appears to develop 
prior to impaired CSF flow, suggesting that this is a model of communicating hydrocephalus 
(Kiefer et al., 1998). Additionally, in the H-Tx strain, the ependymal layer is maintained, which 
is in contrast to the loss of the ependymal layer (ependymal denudation) found in human cases of 
congenital non-communicating hydrocephalus (Jones et al., 2000a; Oi et al., 1996; Yamada et 
al., 1992; Zhang et al., 2006). Although these models have been useful in the study of 
hydrocephalus, the limited penetrance and severe pathology limits their usefulness in 
understanding the pathogenesis of hydrocephalus. 
 Many genetic animal models for studying hydrocephalus have been developed, including 
both models of communicating and non-communicating hydrocephalus. One genetic model of 
hydrocephalus is the hydrocephalus with hop gait (hyh) mice, which have a mutation in -
SNAP, leading to a neural progenitor defect that results in ependymal denudation, aqueductal 
stenosis, and enlargement of the lateral ventricles (Hong et al., 2004; Jimenez et al., 2001; Paez 
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et al., 2007; Wagner et al., 2003). In this model, mice have neural progenitor defects and are 
born with moderate, communicating hydrocephalus. In the first postnatal week, the aqueduct of 
Sylvius closes and severe hydrocephalus develops (Wagner et al., 2003). The development of 
hydrocephalus in this model appears to be dependent on ependymal denudation (Jimenez et al., 
2001; Paez et al., 2007; Wagner et al., 2003). Deficiencies in the L1 neural adhesion molecule 
have been observed in both humans and mice, leading to CRASH syndrome (corpus callosum 
hypoplasia, mental retardation, adducted thumbs, spastic paraplegia and hydrocephalus) (Fransen 
et al., 1995). Hydrocephalus in L1 deficient mice appears to be communicating; the aqueduct 
only becomes stenosed in severe hydrocephalus due to brain compression (Rolf et al., 2001). 
Another genetic model of hydrocephalus are the E2f5 deficient mice, which lack the E2f5 
transcription factor normally expressed in the choroid plexus (CP) (Lindeman et al., 1998). This 
mutation alters the secretory activity of the CP, resulting in a model of communicating 
hydrocephalus with excessive CSF production (Lindeman et al., 1998). Another model of 
hydrocephalus was developed by the insertional inactivation of the transcription factor RFX4 
(Blackshear et al., 2003). Mice heterozygous for this mutation develop hydrocephalus due to the 
absence of the subcommissural organ (SCO). Without the Reissner’s fibers produced by the 
SCO, which are necessary for the patency of the aqueduct in mice, the aqueduct becomes 
stenosed, resulting in non-communicating hydrocephalus (Blackshear et al., 2003; Zhang et al., 
2007). Overexpression of the G-protein coupled receptor, PAC1, in the mouse nervous system 
was also found to cause hydrocephalus, including enlarged lateral and third ventricles; however, 
aqueductal enlargement was also observed, which is rarely observed in human hydrocephalus 
(Lang et al., 2006). Lastly, disruption in the RNA binding protein Msi1 results in aberrant 
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proliferation of the ependymal cells that surround the aqueduct of Sylvius, resulting in non-
communicating hydrocephalus (Sakakibara et al., 2002).  
Multiple models of hydrocephalus have also been developed based on ciliary defects, 
including the hy3 mouse (Davy and Robinson, 2003), the Tg737orpk mouse (Banizs et al., 2005) 
and in mice with a disruption in Mdnah5, a gene that codes for the dynein heavy chain of cilia 
(Ibanez-Tallon et al., 2004). Hy3 mice show defective CSF reabsorption, resulting in 
communicating hydrocephalus with perinatal onset (Davy and Robinson, 2003; Dawe et al., 
2007). In these mice, mild hydrocephalus develops by P14 with moderate ventricular dilation 
and a flattened but intact ependymal lining. As ventricular dilation becomes more severe, the 
ependyma and ependymal cilia of the hy3 mice disappear, especially at the roof of the lateral 
ventricle (Lawson and Raimondi, 1973). Tg737orpk mice present with abnormal ion and water 
transport across the choroid plexus epithelium, resulting in excessive CSF production; stenosis of 
the aqueduct of Sylvius occurs late in the pathogenesis of hydrocephalus in this model (Banizs et 
al., 2005). Hydrocephalus is not the primary pathology in these mice, however; these mice also 
present with cystic kidney disease, sterility, biliary and bile duct hyperplasia in the liver, and 
retinal degeneration (Banizs et al., 2005). In contrast, mice with a mutation in Mdnah5 present 
with non-communicating hydrocephalus caused by a loss of directional CSF flow that leads to 
stenosis of the aqueduct of Sylvius (Ibanez-Tallon et al., 2004).  
In all of these genetic mouse strains, the genetic mutations lead to developmental 
pathologies unrelated to hydrocephalus, making it difficult to identify cellular changes specific to 
the development of hydrocephalus. Additionally, the incomplete penetrance and inability to 
induce hydrocephalus in these models has made it impossible to specifically investigate the 
pathogenesis of hydrocephalus.  
 
Chapter IV 
 
The Ro1 model of hydrocephalus 
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Our understanding of the early changes in hydrocephalus requires the development of 
better animal models. In existing animal models, penetrance is often low and hydrocephalus 
appears to be one of a spectrum of diseases, making it difficult to sort out the cellular 
mechanisms that are contributing to hydrocephalus. Our lab has developed a novel model of 
hydrocephalus that gives us the unique ability to control the onset of the disease and thereby 
study early cellular changes that may lead to the development of hydrocephalus. This model was 
created using the tetracycline-inducible system to drive expression of a mutated Gi-coupled 
GPCR (Ro1 receptor) to cells expressing glial fibrillary acidic protein (GFAP). When mice are 
taken off doxycycline (a tetracycline derivative), allowing for Ro1 expression in GFAP+ cells, 
100% of mice develop hydrocephalus. Unlike other models, hydrocephalus also appears to be the 
primary pathology.  
 The Ro1 RASSL (receptor activated solely by a synthetic ligand) was developed by 
Bruce Conklin’s laboratory by replacing the second extracellular loop (EL2) of the human kappa 
opioid receptor (KOR) with the EL2 of the delta opioid receptor (DOR) (Coward et al., 1998b). 
As such, this receptor represents a transgenic Gi-coupled G protein-coupled receptor (GPCR). 
This receptor was also FLAG-tagged at the amino terminus (Figure 3). This transgenic receptor 
showed a 200-fold decrease in the Ki for dynorphin, an endogenous KOR agonist (Coward et al., 
1998b). A high-throughput screening of 21 endogenous KOR agonists demonstrated that the Ro1 
receptor has significantly reduced affinity for endogenous ligands (Coward et al., 1998b). 
However, binding of the small synthetic drug, spiradoline, was not significantly affected in the 
Ro1 receptor (Coward et al., 1998b). This receptor retained the ability to couple to adenylyl 
cylcase, causing a decrease in cAMP levels (Coward et al., 1998b). Additionally, the inverse 
agonist norbinaltorphamine (norBNI) was capable of inhibiting Ro1 signaling (Scearce-Levie et 
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al., 2005). A tetracycline-inducible system was subsequently used to drive Ro1 to a specific cell 
or tissue type using a cell- or tissue-specific promoter (Figure 4). This technique allowed for 
inducible expression of the receptor, thereby avoiding complications caused by expression 
during development, and cell- or tissue-specific activation of a Gi-coupled GPCR signaling 
cascades.  
 When the cardiac-specific  myosin heavy chain (MHC) promoter was used to drive 
Ro1 expression to the heart, mice developed a lethal cardiomyopathy associated with a wide 
QRS complex arrhythmia (Redfern et al., 2000). These cardiac arrhythmias were blocked by a 
single injection of pertussis toxin (PTX), demonstrating that Ro1 signaling through Gi-coupled 
pathways in the heart caused this arrhythmia (Redfern et al., 2000). Interestingly, these changes 
were due to Ro1 expression alone, suggesting that expression of this receptor is sufficient to 
activate Gi-coupled signaling cascades (Redfern et al., 2000). Additionally, when the Ro1 
receptor was expressed in osteoblasts using the mouse 2.3- type 1 collagen promoter (Col I-
2.3), mice developed trabecular osteopenia (Peng et al., 2008). More specifically, eight weeks of 
Ro1 expression resulted in a greater than 20% reduction in trabecular bone volume compared 
with sex-matched littermate controls (Peng et al., 2008). Again, Ro1 expression alone caused this 
phenotype, suggesting that the Ro1 receptor shows basal signaling in the absence of the agonist, 
spiradoline (Peng et al., 2008). 
 Our laboratory used the tetracycline-inducible system to drive Ro1 expression to GFAP-
positive cells. Immunohistochemistry showed selective co-localization of the FLAG-tagged Ro1 
receptor with GFAP-positive cells in the hippocampus (Figure 5) (Sweger et al., 2007).  
Additionally, Ro1 expression was shown to be regulated by dox. In wild-type control mice or in 
Ro1 mice maintained on dox, the FLAG-tagged Ro1 receptor could not be detected via western 
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blotting; however, when taken off dox, there was clear Ro1 expression in the whole brain, 
hippocampus and cerebellum (Figure 6) (Sweger et al., 2007). Additionally, 100% of double-
transgenic Ro1 mice developed hydrocephalus when taken off dox (Sweger et al., 2007). When 
Ro1 were born to dams maintained off dox, mice developed severely enlarged heads, and by 11 
weeks of age, 50% of Ro1 mice had died (Figure 7) (Sweger et al., 2007).  
 To demonstrate that signaling through the Gi-coupled Ro1 receptor was causing 
hydrocephalus in the Ro1 mice rather than the transgene interfering with cellular machinery, Ro1 
mice and single-transgenic littermate control mice were taken off dox at P30 and injected with 
the KOR antagonist norBNI (7.6 mg/kg, i.p.) every three days for 30 days. The mice were then 
sacrificed, and the lateral ventricle to brain ratio (LV:brain ratio) was measured at the level of the 
striatum and anterior commisure. The LV:brain ratio was significantly higher in Ro1 mice off 
dox than in controls (p = 0.02); however, there were no significant differences in this ratio 
between control mice and Ro1 mice maintained on dox or Ro1 mice maintained off dox and 
given norBNI (Figure 8) (Sweger and McCarthy, 2009). The mitogen-activated protein kinase 
(MAPK) signaling cascade has been shown to be activated downstream of Gi-coupled GPCRs. 
Thus, because signaling through the Gi-coupled Ro1 receptor causes hydrocephalus, changes in 
phospho-ERK were investigated in hydrocephalic Ro1 mice. In P21 mice, phospho-ERK levels 
were shown to be elevated in hydrocephalic Ro1 mice, but not in littermate controls, around the 
lateral ventricles and in the entorhinal cortex (Figure 9) (Sweger et al., 2007). These findings 
implicate Gi-GPCR and MAPK signaling cascades in Ro1-mediated hydrocephalus. Given that 
we are selectively expressing the Ro1 receptor in a specific population of cells and activation of 
a specific signaling cascade is causing hydrocephalus in these mice, this model enables the 
investigation of signaling molecules that may be contributing to hydrocephalus. Additionally, the 
 
complete penetrance and inducibility of this model allow us the unique ability to investigate the 
earliest changes in the pathogenesis of hydrocephalus. Together, these characteristics of the Ro1 
model will increase our understanding of the early pathogenesis of hydrocephalus and may lead 
to the development of novel therapeutics to treat this disorder. 
 
 
Chapter V 
 
Characterization of the histological changes in the pathogenesis  
of hydrocephalus in Ro1 mice 
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Introduction 
Hydrocephalus is a highly prevalent disorder that affects greater than 0.1% of the 
population, yet the primary treatment for hydrocephalus—the surgical placement of shunts to 
drain the excess cerebrospinal fluid—has not changed in over 50 years (Patwardhan and Nanda, 
2005; Piatt and Carlson, 1993; Sainte-Rose et al., 1991). The lack of improved treatments for this 
disorder is due to the multifactorial causes of this disorder and our lack of understanding of the 
early cellular and morphological changes in the pathogenesis of this disorder. In existing animal 
models, penetrance is often low and hydrocephalus appears to be one of a spectrum of diseases, 
making it difficult to sort out the cellular mechanisms that are contributing to hydrocephalus. 
The Ro1 model of hydrocephalus developed by our laboratory has complete penetrance, is 
inducible and is free of complicating pathologies, giving us the unique ability to investigate the 
pathogenesis of hydrocephalus. In this study, we used histology, immunohistochemistry and 
electron microscopy to elucidate the cellular and morphological changes that lead to 
hydrocephalus in the Ro1 model. 
 
Materials and Methods 
Animals. All experiments were performed in accordance with the Institutional Animal Care and 
Use Committee at the University of North Carolina at Chapel Hill and federal guidelines. 
Animals were maintained in climate-controlled housing with a 12 h light/dark cycle and were 
given food and water ad libitum. Selected breeding pairs and weaned mice were given 50 g/mL 
doxycycline (dox; Sigma) in their drinking water, which was changed twice a week. Dox was 
provided in black water bottles to protect the dox from light. Breeding pairs maintained off dox 
were never exposed to dox. 
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Transgenic mice. GFAP-tTA::tetO-Ro1 mice on a KOR knockout background were generated as 
described by Sweger et al., 2007. All mice were backcrossed onto the C57Bl/6J background (10 
generations). 
 
Real-time PCR. Two 1 mm-thick coronal brain sections at the level of the lateral ventricles per 
mouse were sliced on an acrylic matrix and placed in RNA later (Ambion) at -20ºC. RNA was 
isolated using the RNeasy Lipid Tissue Mini Kit (Qiagen), and the amount of RNA per sample 
was quantified using a NanoDrop spectrophotometer (Thermo Scientific). RNA from each 
mouse was sent for an RNA quality check at the Nucleic Acids Core Facility at the University of 
North Carolina. cDNA was then prepared using Superscript II Reverse Transcriptase with 
random primers and RNaseOUT to block RNase activity (Invitrogen). Real-time PCR was then 
conducted using hKOR2 and GAPDH primers and a SYBR green detection system (Applied 
Biosystems).  
 
Hematoxylin and eosin staining. Mice were taken off dox at P30 and transcardially perfused with 
4% paraformaldehyde at 9, 12, 18, 24, 30 and 48 days following dox removal. To study the 
effect of Ro1 expression throughout gestation and development, dams were maintained off dox, 
and weaned mice were perfused at P27. Following perfusion, the brains were removed and post-
fixed overnight at room temperature in 10% formalin with gentle agitation. The brains were then 
rinsed in distilled water and stored in 70% ethanol. The brains were then taken to the University 
of North Carolina histology core facility for paraffin embedding. Serial coronal sections were 
sliced 5 m-thick on a sliding microtome (Leica) and stained with hematoxylin and eosin. 
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Stained brain sections were imaged with a light microscope (Zeiss), and images were captured 
using a Dage Excel XL16 camera (Dage-MTI). 
 
Measurements. Images from hematoxylin and eosin stained coronal brain sections (1.25x 
magnification) at 0.38 mm anterior to bregma were analyzed with MetaMorph image analysis 
software. The maximum width of the lateral ventricles was measured and divided by the 
maximum brain width to obtain the lateral ventricle to brain ratio (LV:brain ratio). For 
measurements of aqueduct disorganization, images of the aqueduct of Sylvius were captured 
from 18, 24, 30 and 48 days off dox mice at 20x magnification immediately posterior to the 
dorsal third ventricle (approximately 2.92 mm posterior to bregma). Aqueduct disorganization 
was scored by three observers blind to genotype based on the continuity of the ependyma and the 
degree of cilia coverage. A maximum score of 10 represented a continuous ependymal lining 
with a thick, continuous carpet of cilia, whereas a minimum score of 0 represented a complete 
loss of ependyma and cilia. 
 
Immunohistochemistry. Mice were taken off dox at P30 and transcardially perfused with 4% 
paraformaldehyde at 9, 12 and 24 days after removal of dox. The brains were post-fixed for 4 h 
in 4% paraformaldehyde at 4ºC and subsequently transferred to a 30% sucrose solution in PBS 
(pH 7.4) at 4ºC for cryoprotection. The brains were then embedded and frozen in O.C.T. 
(Optimal Cutting Temperature; Tissue-Tek, Sakura, Japan) in an ethanol/dry ice bath and stored 
at -80ºC. Ten micrometer-thick coronal and sagittal slices were cut on a cryostat (Reichard-Jung) 
and melted onto Superfrost Plus slides (Fisher). The slices were washed three times with 
phosphate-buffered saline (PBS) and incubated in blocking solution (10% normal goat serum and 
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0.3% TritonX-100 in PBS). The slices were then incubated in primary antibody overnight in 
blocking solution at 4ºC. The primary antibodies used included doublecortin (DCX, 1:500; Cell 
Signaling) to stain for migrating neuroblasts, glial fibrillary acidic protein (GFAP, 1:500; Sigma) 
to stain for astrocytes and S100 (1:500; DAKO) to stain ependymal cells. The slices were then 
washed six times for 10 min in PBS and incubated in goat anti-rabbit 594 or goat anti-mouse 488 
secondary antibodies (Alexa Fluor, 1:400; Invitrogen) in blocking solution for 2 h at room 
temperature. The slices were washed six times for 10 min in PBS and mounted in Vectashield 
with DAPI (Vector), coverslipped and sealed with nail polish. The sections were imaged with a 
fluorescent microscope (Zeiss). 
 
Electron microscopy. Mice were taken off dox at P30 and transcardially perfused at 18 and 30 
days off dox with Ringer’s solution (1.36 M NaCl, 0.127 M Na2HPO4, 0.503 M KCl, 0.098 M 
MgCl2, 0.595 M NaHCO3, 0.204 M CaCl2 and 2.2 mM dextrose, with 0.004% xylocaine to 
anesthetize smooth muscle and 5 U/mL heparin to prevent blood clotting) followed by 2% 
paraformaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer for 10 min at a rate of 3 
mL/min. Brains were post-fixed in the same fixative for 1 h on ice and sliced 50 m-thick on a 
Vibratome (Leica) in ice-cold fixative. The tissue slices were then post-fixed overnight in the 
same fixative at 4ºC. The sections were post-fixed in 0.5% osmium tetraoxide in 0.1 M 
phosphate buffer for 45 min and then stained with 1% uranyl acetate in maleate buffer for 45 
min. After dehydrating in an ascending ethanol series, sections were embedded in Epon/Spurr 
resin (Electron Microscopy Services) and mounted between sheets of Aclar within glass slides. 
After embedding, sections were cut 60 nm-thick on an Ultracut (Leica), mounted onto T200 
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copper grids (Electron Microscopy Services) and post-stained with 2% uranyl acetate and Sato’s 
lead. 
 
Statistics. An F-test was used to calculate a p-value for linear regression analyses. P-values < 
0.05 were considered to be statistically significant. StatView statistical software (version 5.0) 
was used for all statistical tests (SAS). 
 
Results 
Ro1 expression is detectable by 9 days off dox. When taken off dox at P30, Ro1 receptor 
expression was detectable by real-time PCR in 1 mm-thick coronal brain slices at the level of the 
lateral ventricle at 9 days off dox. However, the degree of Ro1 expression varied considerably 
among double-transgenic mice (Figure 10; n = 6). This variability was surprising given that all of 
the mice were derived from the same transgenic lines and all mice were on the C57/bl6 
background. It is possible that this variability is due to variability in the consumption or 
metabolism of dox among the mice. For example, the rate at which dox leaves the fat deposits 
and bone may vary from mouse to mouse, thereby affecting the timing and degree of Ro1 
expression.  
 
Ventriculomegaly and disorganization of the aqueduct of Sylvius are the first signs of pathology 
in the Ro1 model. To determine the early histological changes in the Ro1 model of 
hydrocephalus, Ro1 and littermate control mice were taken off dox at P30 and perfused 9 (n = 4), 
12 (n = 7), 18 (n = 6), 24 (n = 6), 30 (n = 5) and 48 (control, n = 21; Ro1, n = 17) days after 
removal of dox. Serial coronal sections were taken from the beginning of the lateral ventricle 
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through the fourth ventricle and stained with hematoxylin and eosin (H&E). Although we saw 
clear Ro1 receptor expression by 9 days off dox, there were no detectable morphological changes 
at 9, 12 or 18 days off dox. Ventriculomegaly was first observed at 24 days off dox (Figure 11). 
However, likely due to the variability observed in Ro1 receptor expression among double-
transgenic mice, there was considerable variability in ventricle size among Ro1 mice (average 
LV:brain ratio = 0.22; range = 0.14 – 0.39). Ventriculomegaly was more pronounced at 30 and 
48 days off dox (Figure 11), with an average LV:brain ratio of 0.25 at 30 days (range = 0.15 – 
0.43) and 0.38 at 48 days (range = 0.18 – 0.64). Concomitant with the increase in ventricle size, 
we observed disorganization of the ependymal cells and their cilia lining the aqueduct of Sylvius. 
The degree of aqueductal disorganization was highly correlated with the severity of 
ventriculomegaly, as measured by the lateral ventricle to brain ratio (r2 = 0.67; p < 0.0001; 
Figures 12 and 13). Interestingly, there was considerable variability in the size of the aqueduct of 
Sylvius. However, closure of the aqueduct of Sylvius was never observed, despite analysis of 
serial coronal sections from the third to fourth ventricles. These data suggest that the Ro1 model 
is a model of communicating hydrocephalus.  
 
Ependymal denudation of the lateral ventricles is secondary to ventriculomegaly. Ependymal 
denudation of the lateral ventricles often accompanies enlargement of the lateral ventricles in 
humans and other animal models. When taken off dox at P30, brains from Ro1 mice rarely 
showed denudation; denudation was only present with severe ventriculomegaly. However, the 
ependymal lining became thinner with increasing lateral ventricle size (Figure 14). The thinning 
of the ependymal lining observed at the lateral ventricles differed from the considerable 
ependymal cell loss and disorganization observed at the aqueduct of Sylvius. Thus, in the Ro1 
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model of hydrocephalus, ependymal thinning and denudation of the ventricles appears to be a 
consequence of the enlargement of the lateral ventricles, rather than a causative event in the 
pathogenesis of hydrocephalus.  
 
Despite ventriculomegaly, there is no change in subventricular zone organization in early 
hydrocephalus. Because we are driving Ro1 expression to GFAP-positive cells and GFAP is 
expressed in both subventricular zone (SVZ) astrocytes and at low levels in ependymal cells, we 
hypothesized that Ro1 expression might be affecting SVZ organization. Furthermore, SVZ 
astrocytes extend processes that both integrate into the ependymal layer and contact blood 
vessels (Danilov et al., 2009), positioning them to play a potential role in ventriculomegaly and 
ependymal denudation in the pathogenesis of hydrocephalus. These SVZ astrocytes are also the 
progenitor cells of the SVZ, giving rise to neuroblasts that migrate to the olfactory bulb where 
they form olfactory interneurons (Doetsch et al., 1999b; Lois and Alvarez-Buylla, 1994; Luskin, 
1993). Moreover, astrocytes direct the migration of the SVZ-born neuroblasts (Anton et al., 
2004; Conover et al., 2000; Lois et al., 1996). To determine whether Ro1 expression in these 
cells causes changes in SVZ organization and neuroblast migration early in the pathogenesis of 
hydrocephalus, 10 m-thick coronal and sagittal slices were stained with glial fibrillary acidic 
protein (GFAP), an astrocytic marker, S100, an ependymal cell marker, and doublecortin (DCX), 
a marker of migrating neuroblasts. Although there appeared to be thinning of the ependymal 
layer in mice with ventriculomegaly at 24 days off dox, there were no changes observed in the 
number or intensity of staining of astrocytes or ependymal cells at 9 (n = 4), 12 (n = 3) or 24 
days (n = 5) off dox (Figure 15 A-F). Additionally, sagittal slices stained with DCX showed no 
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changes in the number or migration of SVZ-born neuroblasts at 12 (data not shown; n = 3) or 24 
days (n = 5) off dox (Figure 15 G-H). 
 
Ventriculomegaly causes thinning of the ependymal layer, resulting in edema and patches of the 
ventricular wall barren of microvilli. Because no gross morphological changes were observed 
with either H&E staining or immunohistochemistry, transmission electron microscopy was 
performed to investigate the ultrastructure of the ependymal and subependymal layers of the 
lateral ventricles of Ro1 mice early in the development of hydrocephalus. No changes were 
observed in Ro1 mice off dox for 18 days, which corroborates the findings from the light 
microscopy experiments (data not shown; n = 8). However, at 30 days off dox (n = 3), 
considerable thinning of the ependymal layer was observed (Figure 16). Additionally, there were 
patches of the lateral ventricle walls that were barren of microvilli (Figure 16). Edema was also 
present in the periventricular area (Figure 16). 
 
Mice maintained off dox show similar disease progression to mice taken off dox at P30. To 
investigate whether Ro1 expression throughout gestation and development alters disease 
progression in double-transgenic mice, dams were never given dox, and pups were maintained 
off dox until perfusion at P27 (n = 4). Double-transgenic Ro1 mice showed severely enlarged 
heads at P27 (data not shown). Histological analysis using H&E staining showed severe but 
variable ventriculomegaly of Ro1 mice (Figure 17). Interestingly, ependymal denudation was not 
present in any Ro1 mice (Figure 17). Ependymal denudation was only present with severely 
enlarged lateral ventricles, further demonstrating that ependymal denudation is a result of 
ventricular enlargement rather than a causative factor in the development of hydrocephalus in the 
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Ro1 model. Additionally, despite analysis of serial coronal sections from the third ventricle 
through the fourth ventricle, stenosis of the aqueduct of Sylvius was never observed even in the 
most severely hydrocephalic brains studied, although disorganization of the aqueduct was 
present in all Ro1 mice with ventriculomegaly (Figure 17). These data further suggest that the 
Ro1 model is a model of communicating hydrocephalus, as blockage within the ventricular 
system does not appear to be a causative factor for hydrocephalus in this model. 
 
Discussion  
Selectively expressing the transgenic Ro1 receptor in astrocytes using a tetracycline-
inducible system results in a novel and inducible model of hydrocephalus that can be used to 
study the early pathogenesis of this disorder. The careful histological analysis of the Ro1 model 
presented in this study demonstrates that ventriculomegaly and disorganization of the aqueduct 
of Sylvius are the earliest morphological changes observed in the pathogenesis of hydrocephalus 
in the Ro1 model. Ependymal denudation and cilia loss, a common feature of hydrocephalus in 
humans and animal models, appear to result from enlargement of the lateral ventricles. This 
finding suggests that ependymal loss and cilia dysfunction are not a cause of hydrocephalus but 
rather due to the resulting pathology. Interestingly, thinning of the ependymal layer due to 
ventriculomegaly appears to lead to edema and a loss of microvilli lining the walls of the lateral 
ventricles. Other studies have suggested that edema is a result of transependymal flow of CSF 
due to the loss of tight junctions between the ependymal cells caused by ventriculomegaly 
(Jensen, 1979; Rahme and Bojanowski, 2010; Del Bigio, 1993). Furthermore, stenosis of the 
aqueduct of Sylvius, the narrowest part of the ventricular system, was never observed, suggesting 
that the Ro1 model represents a model of communicating hydrocephalus. It is interesting that 
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although the aqueduct never closed, disorganization of the ependyma of the aqueduct was 
observed. The mechanism leading to the disorganization of the aqueduct, as well as the role of 
this disorganization in the pathogenesis of hydrocephalus, remain unclear. The progression of 
hydrocephalus in the Ro1 model appears to be the same, although perhaps more rapid, when 
mice are maintained off dox throughout gestation and development as compared to mice taken 
off dox at P30.  
The Ro1 model of hydrocephalus appears to mirror human hydrocephalus in many 
respects. Multiple studies have suggested that ependymal denudation is subsequent to 
ventriculomegaly and the degree of denudation appears to be dependent on the size of the lateral 
ventricles and the rate at which hydrocephalus progresses; more rapid disease progression leads 
to increased ependymal loss (Bannister and Mundy, 1979; Bruni et al., 1985; Del Bigio, 1993; 
Sarnat, 1995). The progressive loss of microvilli and cilia as well as periventricular edema have 
also been shown to occur in humans with increasing ventricular size and thinning and denudation 
of the ependymal lining (Bannister and Mundy, 1979; Bruni et al., 1985; DaSilva, 2004; Del 
Bigio et al., 1985; Di Rocco et al., 1977). Previous studies have proposed that stretching and 
disruption of the tight junctions of the ependyma secondary to ventricular dilation may result in 
transependymal CSF flow and edema (Levine, 2008; Raimondi, 1994). Interestingly, a previous 
study on human fetuses with moderate communicating hydrocephalus showed consistent 
ependymal denudation. However, all of the fetuses studied presented with ventricular dilation, 
and the ventricular surface area devoid of ependyma increased with increasing severity of 
hydrocephalus and age of the fetus (Dominguez-Pinos et al., 2005). We also observed increased 
ependymal denudation and cilia loss with increasing ventricular size and a correlation between 
the rate of hydrocephalus development and both denudation and cilia density. Whereas extensive 
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denudation and loss of cilia was found in P27 mice maintained off dox throughout gestation and 
development, denudation was rarely observed in Ro1 mice taken off dox at P30, even with 
severe ventriculomegaly. These data suggest that in the Ro1 model the progression of 
hydrocephalus occurs more slowly when hydrocephalus is induced by the removal of dox in 
young adults; this may provide the ependyma with greater time to compensate for the 
enlargement of the ventricles, thereby reducing the degree of denudation observed.  
Subependymal gliosis is commonly observed in humans and animals with chronic 
hydrocephalus; however, gliosis has been shown to be subsequent to ependymal loss (Bruni et 
al., 1985; Del Bigio, 1993). Thus, although we did not observe gliosis early in the pathogenesis 
of hydrocephalus in Ro1 mice, a previous study demonstrated gliosis in the hippocampus and 
cortex of severely hydrocephalic Ro1 mice (Sweger et al., 2007), suggesting that gliosis occurs 
in Ro1 mice with severe hydrocephalus. Although changes in the subventricular zone of human 
fetuses with moderate communicating hydrocephalus have also been observed, these changes 
were shown to be subsequent to ventricular dilation and ependymal loss (Dominguez-Pinos et 
al., 2005). Therefore, it is possible that SVZ disorganization is also present in Ro1 mice, but only 
in mice with severe hydrocephalus and ependymal denudation. 
Many studies in animal models corroborate our findings. Most animal studies of both 
communicating and non-communicating hydrocephalus have shown that ventriculomegaly and 
early tissue damage is accompanied by a flattening, stretching and subsequent disruption of the 
ependyma. For example, in the H-Tx rat and the hy3 mouse models, both of which are models of 
communicating hydrocephalus, ventricular enlargement initially causes stretching of the 
ependyma. However, with more severe ventriculomegaly, ependymal loss occurs, especially at 
the roof of the lateral ventricles (Bannister and Mundy, 1979; Kiefer et al., 1998). Previous TEM 
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studies have also shown stretching of the ependymal layer, intact but widely separated clusters of 
cilia and edematous tissue with enlarged extracellular spaces, which mirrors the results obtained 
in our study (Del Bigio, 1993; Raimondi et al., 1976). Our data from mice maintained off dox 
throughout gestation and development showed that ependymal denudation was most common on 
the roof of the lateral ventricle with severely enlarged ventricles. The Ro1 model of 
hydrocephalus may also be similar to the H-Tx rat in that obstruction of the aqueduct of Sylvius 
may occur only in severely hydrocephalic animals. A previous study on hydrocephalic Ro1 mice 
demonstrated aqueductal stenosis in severely hydrocephalic mice maintained off dox throughout 
gestation and development (Sweger et al., 2007). Although aqueductal stenosis was never 
observed in this study, even in mice with severe ventriculomegaly and a similar dox dosing 
schedule as the previous study, it remains possible that stenosis of the aqueduct of Sylvius may 
require hydrocephalus even more severe than presented herein. It is possible that the loss of cilia 
and ependyma of the aqueduct of Sylvius demonstrated in this study may lead to subsequent 
aqueduct stenosis; ependymal loss of the aqueduct of Sylvius has been proposed to lead to 
aqueduct stenosis and hydrocephalus in the hyh mouse model of hydrocephalus (Jimenez et al., 
2001; Paez et al., 2007; Wagner et al., 2003).  
In sum, the Ro1 model of hydrocephalus represents a novel model of communicating 
hydrocephalus. This model has many similarities to both human hydrocephalus and experimental 
models of hydrocephalus. However, the complete penetrance, inducibility and lack of 
complicating pathologies in this model provide the unique opportunity to investigate the 
pathogenesis of hydrocephalus, which may provide insight into the development and progression 
of this disorder. Moreover, because the Ro1 receptor is a G protein-coupled receptor and is 
restricted to GFAP-positive cells, this model provides the unique ability to investigate specific 
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signaling cascades that may cause hydrocephalus. The data presented herein provide insight into 
the earliest cellular and histological changes in the development and progression of 
hydrocephalus, which may help to improve the early diagnosis and treatment of this disorder.  
 
 
Chapter VI 
 
Astrocyte-specific Ro1 expression causes hydrocephalus but does not affect mouse behavior 
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Introduction  
A variety of behavioral changes have been observed in various animal models of 
hydrocephalus. However, most of these changes appear in mice with severe hydrocephalus and 
the rate of disease progression appears to affect behavioral changes. Nonetheless, reduced swim 
speeds, abnormal gait, hypoactivity and reduced performance on the wire hang and inclined 
slope tests have been demonstrated in various models of hydrocephalus (Del Bigio et al., 1997; 
Del Bigio et al., 2003; Fransen et al., 1998; Khan et al., 2007; Lopes Lda et al., 2009; Tsubokawa 
et al., 1988; Wada, 1988). Additionally, animal models of hydrocephalus have shown reduced 
learning in the Y maze, 8-arm radial maze and Morris water maze tests (Del Bigio et al., 1997; 
Jones et al., 1996; Khan et al., 2007; Miyazawa and Sato, 1991; Miyazawa et al., 1997; Morrisey 
et al., 1996). However, findings from these tests differed considerably depending on the model 
studied. In humans with hydrocephalus, gait abnormalities, motor disorders and memory and 
cognitive defects are the most common behavioral changes (Bakar and Bakar, 2010; Estanol, 
1981; Fletcher et al., 1996; Tarazi et al., 2008; Yeates et al., 2003), which parallels the changes 
found in animal models of hydrocephalus in some respects. However, whether early behavioral 
changes exist prior to apparent pathology, such as ventriculomegaly, remains unknown. A better 
understanding of these early behavioral changes may aid in the early diagnosis of hydrocephalus. 
 
Materials and Methods 
Animals. All experiments were performed in accordance with the Institutional Animal Care and 
Use Committee at the University of North Carolina at Chapel Hill and federal guidelines. 
Animals were maintained in climate-controlled housing with a 12 h light/dark cycle and were 
given food and water ad libitum. Selected breeding pairs and weaned mice were given 50 g/mL 
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doxycycline (dox; Sigma) in their drinking water, which was changed twice a week. Dox was 
provided in black water bottles to protect the dox from light. Breeding pairs maintained off dox 
were never exposed to dox. 
 
Transgenic mice. GFAP-tTA::tetO-Ro1 mice on a KOR knockout background were generated as 
described by Sweger et al., 2007. All mice were backcrossed onto the C57Bl/6J background (10 
generations). 
 
Behavior. To investigate progressive changes in weight and general motor ability, mice 
(controls, n = 11; Ro1, n = 10) were taken off dox at P30, and weight, grip strength (wire hang), 
motor coordination (rotarod), exploratory behavior (open field), startle responses and 
sensorimotor gating (acoustic startle) were measured immediately following removal of dox and 
every week thereafter for a total of seven weeks. For the wire hang test, the mice were placed, 
one at a time, on a wire grid and inverted approximately 20 cm above a soft sponge. The latency 
to fall off of the grid was recorded; the maximum cut-off time was 60 s. For the rotarod test, the 
mice were placed on an accelerating cylinder (rotarod), and the latency to fall off the rotarod was 
recorded; the maximum cut-off time was 300 s. The mice were first given a series of three trials 
to evaluate motor learning; on each subsequent testing day, the mice were given two trials on the 
accelerating rotarod to measure motor coordination. For the open field test, mice were placed in 
a large Plexiglas enclosure with a photobeam array (Accuscan Instruments) and allowed to freely 
explore for 1 h. Total distance traveled (cm), horizontal activity, stereotypy counts and rearing 
activity were measured. For the acoustic startle test, the SR-LAB startle response system was 
used (San Diego Instruments). Briefly, mice were placed in a plexiglas cylinder with white noise 
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at a level of 70 dB. Mice were given a loud startle (120 dB) or a prepulse (74, 78, 82, 86 or 90 
dB) followed by the loud startle (120 dB), and the force displaced by a whole-body startle 
response was measured by an accelerometer. Responses to the startle alone or prepulse followed 
by the startle were randomized; the response to each stimulus was tested six times with 15 s 
between stimuli. 
A second cohort of mice (control, n = 10; Ro1, n = 11) was used to test learning and 
memory in the Morris water maze. The Morris water maze consists of a circular pool (diameter = 
122 cm) partially filled with water (45 cm deep, 24 – 26C) containing non-toxic white paint. 
The pool was visually divided into four quadrants. Visual cues were placed in the room 
surrounding the pool. Visual learning was tested at 10 – 12 days after removal of dox by placing 
the mice in the pool and measuring their latency to swim to a visible platform. Learning 
acquisition of the location of a hidden platform (diameter = 12 cm) was then tested until the 
average latency of the mice was less than 15 s. This test was conducted from 15 – 19 days off 
dox by placing the escape platform below the surface of the water and measuring their latency to 
learn the location of the hidden platform based on the visual cues in the surrounding room. A 
probe trial was then conducted at 19 days off dox by measuring the time spent in each of the 
quadrants; increased time spent swimming in the quadrant where the platform had been 
previously located (quadrant 1) was considered indicative of learning. The platform was then 
moved to the opposite quadrant (quadrant 3) and the time required to learn the new location of 
the platform was measured. Mice were trained in the reversal learning paradigm until the latency 
to find the hidden platform was, on average, less than 15 s. Reversal learning occurred from 22 – 
32 days off dox, and the probe trial for reversal was conducted at 32 days off dox. Mice were 
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then tested for the ability to remember the location of the hidden platform (quadrant 3) by 
recording their latency to find the platform at 46 – 47 days off dox (retention). 
A third group of mice (control, n = 17; Ro1, n = 13) was used to test the development of 
anxiety and depression in early hydrocephalus. At 24 days off dox, mice were tested on the 
elevated plus maze, which has two open arms and two closed arms (20 cm in height). The maze 
is elevated 50 cm from the floor and the arms are 30 cm long. Animals were placed in the center 
section (8 cm x 8 cm) and allowed to freely explore the maze for 5 min. The time spent in the 
open and closed arms and the number of entries into each arm was recorded. Mice were 
subsequently tested in the forced swim test at 25 days off dox. In this test, mice were placed in a 
cylinder (28 cm high; 20.2 cm in diameter) filled with water (14.5 deep; 23C), and their time 
spent immobile in a 6 min-period was recorded. The time spent in the center of the open field 
apparatus (AccuScan Instruments) in 1 h was used as a measure of anxiety in mice 31 days off 
dox. Lastly, passive avoidance was tested in mice 32 – 33 days off dox. The passive avoidance 
test consisted of two trials. On the first day of testing, mice were placed in the apparatus, which 
consists of a light chamber and a dark chamber, separated by a door. After a 30 s acclimation 
period, the door is opened, and when the mice enter the dark chamber, they received a mild 
footshock (0.5 mA, 2 s). On the second day of testing, the latency to enter the dark chamber was 
measured; a 300 s cut-off was used. 
 
Statistics. For comparisons between control and Ro1 mice at a single time point, Student’s t-test 
was used. To analyze changes in the behavioral tests over time as well as changes in the acoustic 
startle test, a repeated-measures ANOVA was used. An F-test was used to calculate a p-value for 
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linear regression analyses. P-values < 0.05 were considered to be statistically significant. 
StatView statistical software (version 5.0) was used for all statistical tests (SAS). 
 
Results 
There are no changes in weight, motor or sensory ability of Ro1 mice with hydrocephalus. Over 
seven weeks of testing, no statistically significant changes in weight were observed between Ro1 
and control mice (Figure 18). Additionally, there were no significant changes in any of the 
measures of the open field test, including total distance traveled (Figure 19), rearing, stereotypy 
or center time. Ro1 mice also did not show reduced motor coordination on the rotarod test or 
reduced startle responses or sensorimotor gating in the acoustic startle test as compared to 
control mice at any week tested (Figures 20 and 21). There were also no changes in grip strength, 
as measured by the wire hang test, between Ro1 and control mice (Figure 22). Of the two Ro1 
mice that died prior to completion of the study, weight, activity, ability on the rotarod and wire 
hang tests and startle responses appeared to drop off immediately prior to death; however, there 
was no correlation between the lateral ventricle to brain ratio and the performance on any of 
these tests. No sex differences were observed in any test. These data are summarized in Table 1 
below. 
 
 
 
 
 
  
Table 1 
Changes in weight and general motor ability of Ro1 mice and littermate controls over seven weeks of testing
  Week 1 
  Control Ro1 p-value
Weight (g) 12.5 ± 0.5 12.7 ± 0.5 0.77
    
Wire hang 58 ± 2 56 ± 4 0.75
(latency, s)   
Rotarod 219 ± 27 229 ± 23 0.79
(latency, s)   
Total distance 5790 ± 563 5816 ± 411 0.97
(cm)   
Startle response 615.8 ± 58.4 520.9 ± 20.7 0.18
(to 120 dB)    
Ro1, n = 10; Control, n = 11 
aWeeks 1, 4 and 7 are shown for simplicity. There were also no significant changes at weeks 2, 3, 5 or 6.
bStudent’s t-test was used to measure differences between Ro1 and control mice at each week; a repeated measures ANOVA was use
all seven weeks of testing. 
cA repeated measures ANOVA across all seven weeks of testing could not be calculated for the wire hang test due to lack of var
 
 
 
 
 
a 
Week 4 Week 7
 Control Ro1 p-value Control Ro1
 18.1 ± 0.67 17.7 ± 0.79 0.71 20.3 ± 0.8 19.7 ± 0.8
     
 60 ± 0 55 ± 5 0.31 60 ± 0 51 ± 7
     
 287 ± 7 232 ± 31 0.08 259 ± 18 250 ± 24
     
 7817 ± 1144 6045 ± 901 0.25 8573 ± 1051 
11817 ± 
2189
     
 970.5 ± 113.3 899.2 ± 94.3 0.65 862.1 ± 98.6 
814.3 ± 
102.0
     
 
iance.
 p-value 
 p-value (7 weeks)b 
 0.67 0.90 
   
 0.15 NAc 
   
 0.77 0.22 
   
 0.16 0.62 
   
 0.75 0.23 
  
d to measure changes across 
 
There are no changes in learning and memory in Ro1 mice with hydrocephalus. The Morris 
water maze was used to assess learning and memory. Ro1 mice were not different from controls 
in their ability to find a visual platform at 10 – 12 days off dox (data not shown). Additionally, 
Ro1 mice learned the location of the hidden platform at the same speed as control mice from 15 
– 19 days off dox (Figure 23) and remembered the location of the hidden platform during the 
probe trial at 19 days off dox (Figure 24). Although ventriculomegaly was likely present in most 
Ro1 mice during reversal learning and the reversal probe trial, the Ro1 mice were not 
significantly different from controls in either of these tests (Figures 25 and 26). However, when 
tested for their ability to remember the location of the hidden platform two weeks later 
(retention), the Ro1 mice showed an increased latency to find the hidden platform, suggesting 
impaired learning as compared to controls, although this difference in latency was not 
statistically significant (Figure 27). However, when lateral ventricle to brain ratio was plotted 
against performance in the retention test, there was a moderate, but significant correlation (r2 = 
0.59; p = 0.026; Figure 28). No sex differences were found in any test. These results are 
summarized in Table 2 below. 
 
Table 2 
Performance of Ro1 mice and littermate controls in the Morris water maze 
  Days off dox Control Ro1 p-value 
Hidden platform acquisition 19 14 ± 2 11 ± 1 0.6 
(latency, trial 4, s)     
Hidden probe trial 21 25 ± 3 23 ± 2 0.86 
(duration quadrant 1, s)     
Reversal platform 
acquisition 32 12 ± 2 16 ± 4 0.93 
(latency, trial 9, s)     
Reversal probe trial 34 14 ± 1 19 ± 3 0.17 
(duration quadrant 3, s)     
Retention 47 18 ± 4 26 ± 6 0.26 
(latency, trial 1, s)     
Ro1, n = 10; Control, n = 11 
 

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Hydrocephalic Ro1 mice show no changes in anxiety, fear or depression. The elevated plus maze 
and the forced swim tests are commonly used measures of anxiety and depression, respectively. 
No changes were found between control and Ro1 mice at 24 and 25 days off dox, respectively, in 
either of these tests (Figures 29 and 30); histological studies suggest that approximately 20% of 
Ro1 mice have clear ventriculomegaly by this time (Table 3). Additionally, no changes in center 
time were found in the open field test, another measure of anxiety, at 31 days off dox (Figure 
31). By this point, approximately 40% of mice display ventriculomegaly (Table 3). Fear 
conditioning and amygdala-dependent learning and memory were tested in the passive avoidance 
test at 32 – 33 days off dox. No significant changes in latency to enter the room where the mice 
had previously received a mild foot shock were recorded (Figure 32). There were no sex 
differences in any of these tests, and no correlations to lateral ventricle to brain ratio were found. 
The results from these tests are summarized in Table 4 below. 
 
Table 3 
Degree of lateral ventricle enlargement in Ro1 mice at various time points following removal of dox at P30 
Days off dox Average LV:brain ratio Range (LV:brain ratio) Percentage of mice with 
a LV:brain ratio > 0.3 
18 0.14 0.10 – 0.18 0% 
24 0.22 0.14 – 0.39 20% (1 of 5) 
30 0.25 0.11 – 0.43 40% (2 of 5) 
48 0.31 0.20 – 0.59 50% (5 of 10) 
 
Table 4 
Assessment of anxiety and depression in Ro1 mice and littermate controls 
  Days off dox Control Ro1 p-value 
Elevated plus maze 24 59.5 ± 4.8 61.5 ± 4.9 0.78 
(open arm time, s)     
Forced swim test 25 81.6 ± 12.5 74.5 ± 8.7 0.66 
(time immobile, s)     
Open field 31 19.6 ± 4.1 25.2 ± 3.8 0.33 
(center time, s)     
Passive avoidance 33 68.3 ± 19.1 42.4 ± 9.8 0.45 
(latency, s)     
Ro1, n = 13; Control, n = 17 
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Discussion 
Although we were surprised to discover a lack of significant behavioral changes in Ro1 
mice even in the presence of ventriculomegaly, our data are perhaps unsurprising considering the 
slow development of hydrocephalus when Ro1 mice are taken off dox at P30. Del Bigio et al. 
(2003) have suggested that a slower rate of disease progression results in less severe 
morphological and behavioral changes. Additionally, studies in H-Tx rats and rats with kaolin-
induced hydrocephalus showed a rapid reduction of motor activity and body weight immediately 
prior to death (Del Bigio et al., 1997; Wada, 1988). In our study we also found hypoactivity, 
reduced rotarod performance and increased latency in the retention test of the Morris water maze 
in mice immediately prior to death. Moreover, studies investigating behavioral changes in animal 
models of hydrocephalus have shown conflicting results. For example, there was no change in 
rotarod performance in juvenile or adult mice injected with kaolin at 7 or 14 days post-injection 
(Lopes Lda et al., 2009) or in kaolin-induced neonatal rats at P20, 19 days after kaolin injection 
(Khan et al., 2006). In contrast, when rats were injected with kaolin to induce hydrocephalus at 
three weeks, there was a significant decrease in rotarod performance at eight months post-
injection (Del Bigio et al., 2003), suggesting that severe hydrocephalus is necessary in the 
kaolin-injected model before behavioral changes on the rotarod are apparent. Del Bigio et al. 
(2003) suggested that there is a threshold of ventricle size beyond which functional changes 
appear, which is dependent on various factors, such as age of onset and rate of ventricular 
enlargement. It is therefore likely that in the Ro1 model, taking the mice off dox to induce 
astrocyte-specific Ro1 expression and hydrocephalus at P30 results in a slow rate of ventricular 
enlargement that reduces the likelihood of observing behavioral changes. It is possible that 
compensation is occurring in the brains of these mice, allowing them to adapt to the gross 
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morphological changes resulting from ventriculomegaly. Considering that we see more rapid 
disease progression in Ro1 mice maintained off dox throughout gestation and development, it is 
possible that Ro1 mice taken off dox at a younger age would show a more rapid rate of 
ventricular enlargement and behavioral changes. It should be noted, however, that the Ro1 
receptor is expressed in astrocytes throughout the brain; therefore, any changes in behavior 
observed in this model may be due to Ro1 affecting astrocyte signaling in a specific brain region 
and may not necessarily be due to hydrocephalus. Taken together, these results suggest that 
treatments that slow the rate of the progression of this disorder may have therapeutic potential by 
allowing the brain to compensate and increasing the therapeutic window for shunt placement or 
alternative treatments. 
 
 
Chapter VII 
 
Lack of demonstrable changes in protein expression in early hydrocephalus 
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Introduction 
Little is known about the early cellular changes that cause hydrocephalus; as a result, 
there are currently no drug-based therapeutic approaches for treating this disease. A handful of 
genomic and proteomic studies have been conducted to address this problem. In 2001, 
Balasubramaniam and Del Bigio published the results from a microarray study in which 
hydrocephalus was induced using the kaolin method (Balasubramaniam and Del Bigio, 2002). 
Kaolin injection into the cisterna magna causes an inflammatory response that results in non-
communicating hydrocephalus. The goal of this study was not to identify early changes in 
hydrocephalus, however. Instead, the authors sought to compare differences in gene expression 
profiles between adult and young hydrocephalic brains. Additionally, the results of their study 
are complicated by the fact that hydrocephalus is secondary to the inflammatory response in the 
kaolin model. Thus, it is not clear whether the changes in gene expression they discovered are a 
result of the induction of hydrocephalus or the inflammation itself. To circumvent this problem, 
Morgan et al. (2005) chose to use a congenital model of hydrocephalus, the H-Tx rat, to conduct 
a microarray study in which they analyzed changes in stress response genes between E18 H-Tx 
rats and age matched Sprague-Dawley (SD) rats (Morgan et al., 2005). Closure of the aqueduct 
and resulting hydrocephalus is thought to occur between E18 and P5 in this model, making E18 a 
good time point to analyze early changes in the pathology of hydrocephalus. They discovered 
distinct heat shock protein gene expression patterns relative to SD rats. However, since the 
authors did not verify hydrocephalus in their rats, and H-Tx rats have a low penetrance of 
approximately 40% (Morgan et al., 2005), this calls into question the validity of their results. 
Additionally, the authors used whole brain for RNA isolation; isolating RNA from tissues most 
likely to be involved in the development of hydrocephalus would have likely yielded differences 
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in gene expression that were much greater in magnitude. A similar report using H-Tx rats to 
understand early gene expression changes in hydrocephalus was published by Miller et al. (2006) 
(Miller et al., 2006). In this study, the authors isolated tissue from the area of the cerebral 
aqueduct of P5 hydrocephalic H-Tx rats and healthy littermate controls. Interestingly, they found 
only a small number of genes that were differentially expressed: 47 transcripts were changed, 23 
of which have known functions. However, with this study there is the concern that they are 
investigating effects secondary to the development of hydrocephalus, since at P5 the authors 
noted that the rats already had enlarged lateral ventricles. Therefore, an earlier time point would 
be necessary to identify early changes central to the development of hydrocephalus. With the H-
Tx model, however, this is not possible since penetrance is low and the only way to ensure that 
the rats studied will develop hydrocephalus is to wait until the disease is already present.  
Currently, there is only one proteomic study that has been conducted to investigate early 
changes in the development of hydrocephalus. Li et al. used 2D-gel electrophoresis and mass 
spectrometry to investigate changes in protein expression among P1 hydrocephalic H-Tx rats, 
age-matched littermate controls, and P1 Sprague-Dawley rats (Li et al., 2005). The authors 
identified 7 proteins altered in H-Tx rats at this stage, which included HMG-1, CDCrel-1A, 
mitochondrial ATP synthase, ERp29, NADP+-ICDH, CCT  and . These changes suggest that 
at P1, H-Tx rats have abnormal energy metabolism and protein folding, which implies that 
congenital hydrocephalus may be related to mitochondrial and ER dysfunction. However, as with 
the study by Miller et al., these rats already had an enlarged cranium; therefore an earlier time 
point is necessary to investigate early changes that lead to hydrocephalus. Additionally, 2D gel-
electrophoresis and mass spectrometry can only identify a handful of altered proteins. As a 
result, in this study, we investigated early protein and phospho-protein expression changes in 
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early hydrocephalus using antibody microarrays, western blotting and immunohistochemistry. A 
large-scale antibody microarray was used to investigate changes in 800 proteins, including 300-
phospho-specific antibodies (Pelech and Zhang, 2007). Because our mice have 100% penetrance 
and no complicating pathologies, we have the unique ability to investigate early changes in the 
development of hydrocephalus. Changes in protein and phospho-protein expression were 
analyzed via antibody microarrays and western blotting at 9 days following the removal of 
doxycycline; at this time point, there is expression of the Ro1 receptor detectable by real-time 
PCR (Figure 10), but no histological changes in brain or cellular morphology are observed. The 
strength of the antibody microarray approach lies in its ability to analyze changes across a large 
number of proteins in an unbiased manner. Considering that there is no definite pathological 
hypothesis as to how hydrocephalus develops, there is no hypothesis to prove or disprove; rather, 
the goal of this study was to create a breakthrough in our understanding of the mechanisms that 
cause hydrocephalus. However, as a result of the high false negative rates of this approach, 
immunohistochemical analysis of various proteins and phospho-proteins likely to play a role in 
the Ro1 model of hydrocephalus was also conducted. Further, primary astrocyte cell culture with 
western blotting was used to investigate signaling cascades activated downstream of the Ro1 
receptor. Together, the goal of these approaches was to identify early changes in protein and 
phospho-protein expression in the development of hydrocephalus that may be contributing to the 
pathophysiology of this disorder.  
 
Materials and Methods 
Ependymal and subependymal cell dissection and lysis. Mice were taken off dox at P30 and 
sacrificed for analysis of protein expression and phosphorylation levels at 9 days off dox. 
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Following anesthesia with isoflurane, double-transgenic Ro1 and single-transgenic control mice 
were decapitated, and their brains were cut into 1 mm-thick coronal sections using an acrylic 
matrix. The slices containing the lateral ventricles were immediately transferred to ice-cold 
dissection buffer, containing 20 mM MOPS, pH 7.0, 2 mM EGTA, 5 mM EDTA, 30 mM 
sodium fluoride, 60 mM -glycerophosphate, 20 mM sodium pyrosphosphate, 1 mM sodium 
orthovanadate, 1 mM phenylmethylsulfonylfluoride, 3 mM benzamidine, 10 M leupeptin and 2 
mg/mL pepstatin A. The ependymal and subependymal layers were dissected from the lateral 
ventricles using 30 gauge needles and transferred to a 0.5 mL centrifuge tube containing 100 L 
of dissection buffer. Tissue was pooled from four mice per genotype to generate enough protein. 
Following the dissections, the samples were spun at 1000 xg for 10 min at 4ºC to pellet the 
tissue. The dissection buffer was then removed, and 60 L of lysis buffer was added. The lysis 
buffer consisted of dissection buffer plus 1% Triton X-100 and 1 mM dithiothreitol (DTT). 
Samples were then sonicated four times for 10 s and spun at 90,000 xg for 30 min at 4ºC. The 
supernatant fraction was transferred to a new tube and subjected to the Thermo 660 nm protein 
assay (Thermo Scientific). The lysates were then stored at -80C. 
 
Kinexus antibody microarray. For the Kinexus antibody microarray, tissue was prepared as 
described in “Ependymal and subependymal dissection and lysis.” The tissue lysates were 
shipped to Kinexus overnight on dry ice and run on their 800 antibody microarrays. These arrays 
contain 300 phospho-site specific antibodies and 500 antibodies for total protein. Additionally, 
for each sample analyzed, each antibody is spotted twice as a quality control measure. “Hits” 
were identified based on fold change from control and quality control parameters.  
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Primary astrocyte cell culture. P0 – 2 pups were sterilized with 70% ethanol and decapitated. 
The brain was then removed, and the cortex was peeled away and placed in Hank’s Balanced 
Salt Solution containing calcium and magnesium (HBSS+; Invitrogen). The meninges were then 
removed with fine forceps, and each hemisphere of the cortex was cut into 2 – 3 pieces and 
placed into fresh HBSS+. The cortical pieces from each pup were placed into a separate 35 mm 
dish with HBSS+, and tail cuttings were taken for genotyping. The pieces of cortex were then 
transferred to a 14-mL Falcon tube (BD Biosciences) with 1 mL of 1x Trypsin-EDTA (CellGro), 
and incubated for 30 min at 37ºC at 100 rpm. Following incubation, 1 mL of Dulbecco’s 
Modified Eagle Medium – high glucose (DMEM-H; CellGro), containing 10% fetal bovine 
serum (CellGro), penicillin/streptomycin and glutamine, was added. The tissue pieces were then 
titrurated using a 5 mL transfer pipet, and tissue pieces from each mouse were placed in a 
separate well in a 6-well plate containing DMEM-H. The 6-well plates were then placed in an 
incubator at 37C and 95%O2/5%CO2. Half of the media was changed the subsequent day, and 
all of the media was changed two days after the initial culture. The media was then changed 
every two days. 
 
Real-time PCR. For real-time PCR experiments, cultured astrocytes from four pups per genotype 
were combined into a 25 cm2 flask, 10 days after the initial culture. Twenty-five days later, RNA 
was isolated using the RNeasy Lipid Tissue Mini Kit (Qiagen), and the amount of RNA per 
sample was quantified using a NanoDrop spectrophotometer (Thermo Scientific). RNA from 
each mouse was sent for an RNA quality check at the Nucleic Acids Core Facility at the 
University of North Carolina. cDNA was then prepared using Superscript II Reverse 
Transcriptase with random primers and RNaseOUT to block RNase activity (Invitrogen). Real-
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time PCR was then conducted using hKOR2 and GAPDH primers and a SYBR green detection 
system (Applied Biosystems).  
 
Immunocytochemistry. For FLAG staining of cultured astrocytes, cultured astrocytes were split 
12 days after initial culture onto poly-D-lysine coated coverslips (BD Biosciences); two pups per 
genotype were combined for staining. Three days later, the cells were rinsed in HBSS and fixed 
for 15 min in 4% paraformaldehyde (PFA) in 1x phosphate-buffered saline (PBS). Cells were 
then washed three times for 5 min in 1x PBS and permeabilized for 10 min in ice-cold methanol. 
Following washes in 1x PBS, the cells were blocked in 5% normal goat serum (NGS) and 0.3% 
Triton-X100 in 1x PBS for 1 h at room temperature. The cells were then incubated overnight in 
primary antibodies in antibody dilution buffer, containing 1% bovine serum albumin and 0.3% 
Triton-X100 in 1x PBS at 4ºC. The primary antibodies used were mouse anti-GFAP (1:500; 
Sigma) to stain for astrocytes and rabbit anti-FLAG (1:500; Sigma) to stain for the FLAG-tagged 
Ro1 receptor. Following washes in 1x PBS, the cells were incubated in antibody dilution buffer 
for 2 h at room temperature in the following secondary antibodies: goat anti-mouse Alexa Fluor 
488 (1:400; Invitrogen) and goat anti-rabbit Alexa Fluor 594 (1:400; Invitrogen). After washing 
in 1x PBS, the cells were mounted onto glass slides in Vectashield plus DAPI mounting media 
(Vector Laboratories) and imaged with a fluorescent microscope (Zeiss). 
 
Western blotting. For western blotting on tissue lysates derived from Ro1 and control mice at 9 
days off dox, the tissue was prepared as described in “Ependymal and subependymal cell 
dissection and lysis.” Twenty micrograms of tissue lysates (except phospho-RSK, 40 g) were 
added to 5x loading buffer and heated at 95C for 5 min. The lysates were then loaded onto a 
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10% Tris-glycine gel and subjected to SDS-PAGE at 120 V. Four samples per genotype were run 
on each gel. The proteins were then transferred to nitrocellulose at 100 V for 1 h at room 
temperature. The membranes were blocked for room temperature for 1 h in 5% milk for all 
antibodies except ERK and phospho-ERK, which were blocked in 3% gelatin. The blots were 
then incubated overnight at 4ºC in primary antibody (all 1:1000), washed in TBST and incubated 
in HRP-conjugated secondary antibody (goat anti-rabbit or goat anti-mouse, 1:5000; Jackson 
ImmunoResearch) for 2 h at room temperature. Following washes in TBST, ECL reagent 
(SuperSignal West Pico, Thermo Scientific) was applied for 5 min and blots were exposed to 
film and developed. To ensure even loading, blots were stripped with RestoreTM stripping buffer 
(Thermo Scientific) for 15 min at room temperature before reprobing with actin (Sigma). For 
p38, phospho-c-Jun, Bcl-2, MKK4, MKK3, RSK and phospho-RSK, the primary antibody 
(1:1000) was incubated in 5% bovine serum albumin (BSA) in TBST, and the secondary 
antibody was incubated in 1% non-fat dry milk in TBST. For ERK and phospho-ERK (1:1000), 
the primary and secondary antibodies were incubated in 1% gelatin. For actin, the primary and 
secondary antibodies were incubated in 1% mik. All primary antibodies were purchased from 
Cell Signaling except the actin antibody, which was purchased from Sigma. 
 For western blotting on cultured astrocytes, cells were cultured in 6-well plates, as 
described in “Primary astrocyte cell culture,” until confluent (9 days after initial culture). The 
cells were then gently washed with 1x PBS and lysed on ice with ice-cold lysis buffer, 
containing 20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 
mM PMSF, 2 mM sodium vanadate, 20 mM sodium fluoride, 0.05 mM DTT, 1 mg/mL leupeptin 
and 17 mg/mL aprotinin. Cells were then transferred to a microcentrifuge tube on ice, vortexed 
and incubated on ice for 10 min with occasional vortexing. The lysates were then spun at 13,000 
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rpm for 10 min at 4ºC, and the supernatant was transferred to a fresh microcentrifuge tube. The 
Thermo 660 nm (Thermo Scientific) protein assay was used to determine the concentration of 
protein per lysate. Lysates were stored at -80ºC until use. Western blotting for ERK and 
phospho-ERK was conducted as previously described, loading seven samples per genotype on a 
single gel.   
 
Immunohistochemistry. Mice were taken off dox at P30 and transcardially perfused at 12, 18 and 
24 days off dox with 4% paraformaldehyde (PFA). The brains were then removed and post-fixed 
in 4% PFA for 4 h and cryoprotected in 30% sucrose at 4ºC. The brains were then frozen in 
O.C.T. (Optimal Cutting Temperature, Sakura, Japan) on dry ice and stored at -80ºC. The brains 
were sliced 10 m thick on a cryostat and mounted onto glass slides. Following washes in 1x 
PBS, the tissue was blocked for 1 h in 4% normal goat serum (NGS) and 1% BSA in 1x PBS. 
The tissue was then incubated overnight at 4ºC in aquaporin 4 (1:100; Santa Cruz 
Biotechnology) and GFAP (1:500; Sigma) primary antibodies in 0.25% Triton X-100 and 1% 
DMSO in 1x PBS. Following washes in 1x PBS, the tissue was incubated in goat anti-rabbit 
Alexa Fluor 594 and goat anti-mouse Alexa Fluor 488 (1:400; Invitrogen) for 1.5 h at room 
temperature in 0.25% Triton X-100 and 1% DMSO in 1x PBS. The tissue slices were then 
washed, mounted with Vectashield plus DAPI (Vector Laboratories) and coverslipped. Staining 
was imaged using a fluorescent microscope (Zeiss). 
 
Results 
There are no proteins or phospho-proteins with significantly altered levels of expression in vivo 
in early hydrocephalus. Using a log2(fold change) cutoff of greater than 0.5 or less than –0.5, 
 
which corresponds to a 40% change from control, and filtering the dataset for various quality 
control measures, 55 proteins or phospho-proteins were found to be altered consistently across 
all three paired samples. The log2(fold change) was used because this value linearizes the data; as 
a result, this is a better measure of the degree of change because the fold change and the percent 
change from control (%CFC) underestimate the magnitude of the decreases. This list was further 
reduced based on consistency across samples and quality parameters, including the signal to 
noise ratio and the variability between the two spots for each antibody on the array. Table 5 
shows the final list of proteins and phospho-proteins with a log2(fold change) greater than 0.5 or 
less than -0.5 across three paired samples, each of which were prepared on the same day.  
Table 5  
Changes in protein and phospho-protein expression levels across three paired samples analyzed on the Kinexus 
antibody microarrays 
Protein abbreviation (phospho-site) and full name Sample 1: Log2 
(%CFC) 
Sample 2: Log2 
(%CFC) 
Sample 3: Log2 
(%CFC) 
Bcl2 (Pan) B-cell lymphoma protein 2 -0.73 (-40) -1.3 (-59) -1.55 (-66) 
EGFR (Pan) Epidermal growth factor receptor-tyrosine 
kinase 
1.22 (134) 0.82 (76) 0.88 (84) 
Erk1 (Pan) Extracellular regulated protein-serine kianse 1 
(p44 MAPK) 
2.68 (542) 1.80 (248) 2.25 (377) 
Erk1 (T202+Y204; T185/Y187) Extracellular regulated 
protein-serine kianse 1 (p44 MAPK) 
1.35 (155) 0.96 (94) 0.67 (59) 
FAK (Y397) Focal adhesion protein-tyrosine kinase -0.93 (-48) -0.74 (-40) -1.03 (-51) 
FAK (Y576) Focal adhesion protein-tyrosine kinase -0.72 (-39) -0.93 (-48) -0.76 (-41) 
FGFR1 (Pan) Fibroblast growth factor receptor-tyrosine 
kinase 1 
-1.03 (-51) -2.13 (-77) -1.11 (-54) 
FKHRL1 (T32) Forkhead-like transcription factor 1 
(FOXO3A) 
-0.67 (-37) -1.22 (-57) -1.51 (-65) 
GFAP (S8) Glial fibrillary acidic protein -0.96 (-48) -0.94 (-48) -1.20 (-56) 
GRK3 (Pan) G protein-coupled receptor-serine kinase 3 -0.76 (-41) -0.98 (-49) -1.40 (-62) 
GSK3b (Pan) Glycogen synthase-serine kinase 3 beta -1.25 (-58) -1.20 (-56) -1.53 (-63) 
Histone H1 (phospho CDK1 sites) 0.96 (95) 1.26 (140) 0.63 (55) 
Histone H2A.X (S139)  0.78 (71) 0.87 (83) 1.21 (131) 
IKK (Pan) Inhibitor of NFB protein-serine kinase 
alpha 
-1.08 (-53) -1.20 (-57) -1.38 (-62) 
Jun (S73) Jun proto-oncogene-encoded AP1 transcription 
factor 
0.72 (65) 0.64 (56) 0.53 (44) 
MEK3b (MAP2K3) (Pan) MAPK/ERK protein-serine 
kinase 3 beta isoform 
-0.98 (-49) -0.5 (-30) -1.16 (-55) 
MEK4 (MAP2K4) (Pan) MAPK/ERK protein-serine 
kinase 4 (MKK4) 
-1.79 (-71) -1.42 (-63) -0.82 (-55) 
MEKK1 (MAP3K1) (Pan) MAPK/ERK kinase kinase 1 -0.63 (-35) -0.79 (-42) -0.99 (-51) 
MEKK2 (MAP3K2) (Pan) MAPK/ERK kinase kinase 2 -0.68 (-38) -0.86 (-45) -0.74 (-40) 
 
p38g MAPK (Erk6) (Pan) Mitogen activated protein-
serine kinase p38 gamma 
-0.61 (-34) -0.60 (-34) -0.64 (-36) 
PKA R1a (Pan) cAMP-dependent protein-serine kinase 
type I-alpha regulatory subunit 
-1.53 (-65) -1.08 (-53) -0.81 (-43) 
RSK1 (Pan) Ribosomal S6 protein-serine kinase 1 -1.31 (-60) -0.92 (-47) -1.33 (-60) 
RSK1/2/3 (T573/T477) Ribosomal S6 protein-serine 
kinase 1/2/3 
-0.56 (-32) -1.12 (-54) -1.23 (-57) 
 
A signaling pathway diagram for these changes in protein and phospho-protein 
expression was then created to illustrate how potential signaling pathways may be altered early 
in the Ro1 model of hydrocephalus (Figure 33). Interestingly, there was a consistent increase in 
phospho-ERK levels in the Ro1 mice; ERK has been shown to be activated downstream of the 
KOR and is therefore likely to be activated by the Ro1 receptor (Bruchas et al., 2008; Bruchas 
and Chavkin, 2010). Additionally, past studies in our laboratory have demonstrated that 
phospho-ERK staining is increased in Ro1 mice as compared to controls (Sweger et al., 2007). 
 Western blotting was then used to confirm the changes observed in the antibody 
microarray analysis. However, no changes were found via western blotting for p38, phospho-c-
jun, Bcl-2, phospho-ERK, ERK, MKK4, MKK3, RSK or phospho-RSK at 9 days off dox (data 
not shown). 
 
Despite Ro1 expression, primary astrocyte cultures do not show changes in phospho-ERK 
expression, a protein known to be activated downstream of the Ro1 receptor. Although the 
primary astrocyte cultures were shown to expression the Ro1 receptor via real-time PCR and 
FLAG staining (Figures 34 and 35), there were no changes in phospho-ERK expression after 9 
days in culture (data not shown). 
 
 
 
Considerable variability in aquaporin 4 expression is present early in hydrocephalus. 
Immunohistochemistry was used to analyze changes in aquaporin 4 expression at 12, 18 and 24 
days off dox. Although there was a trend suggesting a decrease in aquaporin 4 expression at 18 
days off dox (Figure 36), due to the high degree of variability of staining among mice, no 
statistically significant changes were observed between Ro1 and control mice at any time point 
analyzed. 
 
Discussion 
Nine days off dox may be too early to observe changes in protein or phospho-protein expression 
in the Ro1 model of hydrocephalus. Most of the changes in protein or phospho-protein 
expression found using the antibody microarray analysis were small and none were confirmed 
via western blotting, suggesting that there may be no changes in protein expression at 9 days off 
dox. Preliminary studies in our laboratory suggested that ependymal denudation was present at 9 
days off dox, resulting in the selection of this time point for the antibody microarray analysis. 
However, further and more careful histological analysis of the progression of hydrocephalus in 
the Ro1 model (see Chapter IV) revealed that ependymal denudation does not occur until severe 
ventriculomegaly is present and was not observed prior to 48 days off dox. Additionally, in this 
careful histological analysis, no morphological or cellular changes were found until 24 days off 
dox, at which point ventriculomegaly and disorganization of the aqueduct of Sylvius was 
observed in approximate 33% of mice (Chapter IV). Therefore, it is likely that 9 days off dox 
was too early a time point to observe changes in protein or phospho-protein expression in the 
pathogenesis of hydrocephalus in the Ro1 model. Future studies using western blotting or 
immunohistochemistry to investigate changes in protein and phospho-protein expression at a 
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later time point may reveal early changes that contribute to the development of hydrocephalus in 
this model. 
 Additionally, it is possible that the wrong cell type was isolated for analysis. As 
previously mentioned, prior studies in our laboratory suggested that ependymal denudation was 
the earliest change observed in the pathogenesis of hydrocephalus in the Ro1 model; therefore, 
the ependymal and subepenymal cells were isolated for analysis for antibody microarrays and 
western blotting. However, the careful histological analysis described in Chapter IV 
demonstrated that ependymal denudation at the lateral ventricles is a result of severe enlargement 
of the ventricular walls and not a causative factor in the development of hydrocephalus in this 
model. Therefore, it is possible that the wrong population of cells was isolated for these studies. 
The use of fluorescent-activated cell sorting (FACS) to selective isolate and analyze GFAP-
positive astrocytes (Cahoy et al., 2008), which should be expressing the Ro1 receptor, may 
provide better insight into the early signaling events that lead to the development of 
hydrocephalus in this model. 
 
Considerable variability in rate of disease progression in Ro1 mice makes analysis of changes in 
protein or phospho-protein expression difficult. As shown in Figure 10 in Chapter IV, there is 
considerable variability in the degree of Ro1 expression among Ro1 mice. It is likely that this 
variability is contributing to the variability we observe in the rate of the development of 
hydrocephalus in Ro1 mice (Chapter IV). Due to this variability in the rate of disease progression 
among Ro1 mice, it is perhaps unsurprising that there was considerable variability observed in 
aquaporin 4 expression among Ro1 mice. As a result, although there was a trend suggesting a 
reduction in aquaporin staining at 18 days off dox, this reduction was not significant. If Ro1 
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expression levels correlate with rate of disease progression, then it is possible that correlating 
levels of Ro1 expression using real-time PCR with immunohistochemistry on fresh frozen brain 
tissue from the same mouse may reveal changes in protein or phospho-protein expression at a 
specific level of Ro1 expression. 
 
Difficulties in mimicking Ro1 signaling in vitro. Although increases in phospho-ERK expression 
have been previously shown around the lateral ventricles and in the entorhinal cortex of Ro1 
mice, there were no changes in phospho-ERK expression in primary astrocytes cultures (n = 7). 
This lack of changes in phospho-ERK expression was demonstrated despite expression of the 
Ro1 receptor, as detected by real-time PCR and FLAG staining. It is possible that 9 days in 
culture without dox was not the correct time point to observe changes in phospho-ERK 
expression; receptor expression may have been too low at this time point or, more likely, 
receptor downregulation may have occurred, thereby reducing Ro1 signaling. Because dox 
leaves bone and adipose tissue slowly, it takes longer for dox to be completely removed in vivo, 
resulting in a relatively slow onset of Ro1 expression. In contrast, in vitro, the dox is eliminated 
as soon as the cells are cultured. As a result, Ro1 expression should be present shortly after 
culturing. However, it is unclear what dose of dox primary astrocyte cultures should be given to 
suppress Ro1 expression and at which point following removal of dox from cultured astrocytes 
Ro1 signaling mimics that which we observe in vivo. Therefore, the feasibility of using primary 
astrocyte cultures for examining Ro1 signaling in vitro is questionable. 
 
 
 
 
Gi-coupled GPCR signaling and possible role in hydrocephalus. The Ro1 receptor was created 
by removing the second extracellular loop of the kappa opioid receptor and replacing it with the 
second extracellular loop of the delta opioid receptor (Coward et al., 1998a; Redfern et al., 1999; 
Scearce-Levie et al., 2005; Sweger et al., 2007). Because both of these receptors are Gi-coupled 
GPCRs, it is likely that the Ro1 receptor also signals via Gi-coupled GPCR pathways. The major 
signaling pathways shown to be activated downstream of the KOR and other Gi-coupled GPCRs 
include inhibition of adenylyl cyclase, modulation of calcium and potassium channels and 
activation of the mitogen-activated protein kinase (MAPK) family, including ERK1/2, p38 and 
JNK (Bruchas and Chavkin, 2010).  
The G subunit of Gi-coupled GPCRs has been shown to directly activate the inwardly 
rectifying potassium channel, Kir3, and reduce conductance through voltage-gated calcium 
channels (Krapivinsky et al., 1995; Sadja et al., 2003; Wickman and Clapham, 1995). 
Interestingly, KOR activation has been suggested to mobilize intracellular calcium via the 
inositol tris-phosphate (IP3) pathway (Spencer et al., 1997), and kappa opioids have been shown 
to increase intracellular calcium in astrocytes (Gurwell et al., 1996; Stiene-Martin et al., 1993). 
However, it is possible that this calcium mobilization is due to the KOR promiscuously coupling 
to Gq-coupled G proteins (Bruchas and Chavkin, 2010). 
GRK3- and arrestin-mediated desensitization and internalization of the KOR have been 
shown to recruit MAPKs, the best characterized of which is ERK1/2 (Bruchas and Chavkin, 
2010). Interestingly, ERK1/2 activation in astrocytes was shown to stimulate the proliferation of 
astrocytes (McLennan et al., 2008), and previous studies in our laboratory have demonstrated 
that basal levels of Ro1 signaling activate phospho-ERK (Sweger et al., 2007). ERK1/2 has also 
been shown to be activated downstream of KOR in an arrestin-independent manner (McLennan 
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et al., 2008). Activation of ERK1/2 is known to activate cAMP response element binding protein 
(CREB), a transcription factor that controls the expression of several proteins. p38 has also been 
shown to be activated downstream of the KOR in astrocytes and is thought to be arrestin-
dependent (Bruchas et al., 2006; Bruchas et al., 2007a). p38 activation leads to the production of 
inflammatory cytokines in astrocytes as well as the induction of nitric oxide synthase (Ashwell, 
2006). Other studies have shown p38-induced Src activation following stimulation of the KOR 
(Clayton et al., 2009). Although there have been fewer studies on opioid receptor-mediated 
activation of JNK, arrestin-dependent activation of JNK has been shown downstream of Gi-
coupled GPCR activation (Kam et al., 2004; McDonald et al., 2000; Song et al., 2009). 
Additionally, KOR activation has been shown to cause protein kinase B (PKB)-dependent JNK 
phosphorylation (Bruchas et al., 2007b; Kam et al., 2004). 
Additionally, GPCR promiscuity has been demonstrated in other systems, especially 
upon overexpression of the receptor (Hermans, 2003); as such, with high levels of expression and 
high basal activity of the Ro1 receptor, it is possible that receptor promiscuity is also occurring 
in our mice. As a result, it is unclear which signaling pathways are being activated by Ro1 
expression to cause hydrocephalus. Future studies involving FACS sorting with antibody 
microarrays and western blotting at various time points to investigate changes in signaling 
pathways in the development of hydrocephalus in the Ro1 model may provide insight into the 
pathogenesis of this disorder. Additionally, correlating levels of Ro1 expression to changes in 
protein and phospho-protein expression via real-time PCR and immunohistochemistry, 
respectively, may aid in the determination of Ro1-mediated changes in protein and phospho-
protein expression that lead to hydrocephalus in this model. 
 
Chapter VIII 
 
Discussion 
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a. Current problems in hydrocephalus research and treatment  
There have been few improvements in the treatment and diagnosis of hydrocephalus 
since shunt placement surgery was developed over 50 years ago, in large part due to limited 
clinical and basic research focused on understanding hydrocephalus. This is astounding 
considering that the prevalence of hydrocephalus is high, affecting 0.1% of the population 
(Patwardhan and Nanda, 2005). Unfortunately, with the development of shunt surgery for the 
treatment hydrocephalus, research into other treatments of hydrocephalus slowed considerably. 
This is especially unfortunate because shunt infection and failure are extremely common, with 
two-thirds of shunts failing within a ten-year period, and most individuals suffering from 
hydrocephalus require multiple shunt revision surgeries throughout their lives (Patwardhan and 
Nanda, 2005). Further research into the pathogenesis, pathology and recovery mechanisms of 
hydrocephalus are necessary to improve the diagnosis and treatment of this disorder. 
 The vast majority of hydrocephalus cases are idiopathic in nature. It is likely that many of 
these cases result from aberrant signaling within the CNS; however, to date, few proteins and 
signaling pathways have been implicated in the development of hydrocephalus. The only 
signaling pathways identified to play a possible role in the development of hydrocephalus were 
demonstrated through the creation of transgenic mice. Suppressor of cytokine signaling 7 
(SOCS7) knock-out mice and mice with overexpression of the pituitary adenylate cyclase-
activating polypeptide receptor type 1 (PAC1) developed hydrocephalus (Krebs et al., 2004; 
Lang et al., 2006). Thus, it is possible that phosphatidylinositol-3 kinase (PI3K), phospholipase 
C (PLC) and the Jak/STAT pathway, which are downstream of SOCS7, as well as protein 
kinases A and C (PKA and PKC), which are activated downstream of the PAC1 receptor, may 
play a role in the development of hydrocephalus (Lang et al., 2006; Martens et al., 2005; 
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Matuoka et al., 1997). Genomic and proteomic studies have shown altered expression of proteins 
involved in energy metabolism and the stress response in hydrocephalic rats (Li et al., 2005; 
Morgan et al., 2005); however, further investigation is necessary to determine if these changes 
are specific to hydrocephalus and are involved in the development of this disorder. The Ro1 
receptor also implicates Gi-coupled GPCR signaling in the pathogenesis of hydrocephalus; 
however, the specific signaling pathways leading to hydrocephalus in this model remain unclear.  
 Most of our current knowledge of hydrocephalus is related to the secondary 
neuropathological changes resulting from hydrocephalus, some of which can be improved or 
reversed by shunting. These pathological changes are discussed in more detail in Chapter III and 
include ependymal loss, reactive gliosis, periventricular edema, white matter loss, destruction of 
periventricular axons and atrophy of dendritic processes, decreased levels of neurotransmitters 
and reduced metabolism. These changes lead to severe defects in motor coordination, cognition 
and quality of life in hydrocephalic individuals. However, our understanding of how these 
changes develop and how treatment is capable of reversing these changes is extremely limited. 
The development of new drugs to treat these neuropathological changes, especially those 
changes unaffected by shunting, may improve patient outcome after shunt surgery.  
 Although pharmacological therapy to treat or prevent hydrocephalus is the ultimate goal, 
new medical devices and/or procedures for the treatment of hydrocephalus are required in the 
interim. For example, the development of shunts with reduced risk of infection or blockage 
would greatly reduce the need for shunt revision in patients with hydrocephalus. Drake and 
colleagues suggest that neurosurgeons should be able to achieve a one-year failure rate of 5%, 
including an infection rate of 1%, in the near future (Drake et al., 2000). They suggest that 
improvements in mathematical models to better understand the interactions between the patient 
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and the shunt, animal models of shunt failure to improve our understanding of the mechanisms of 
catheter occlusion, ongoing clinical trials and new shunts designs and materials will enable 
neurosurgeons to reach this goal (Drake et al., 2000). Additionally, the development and use of 
devices that record the ICP and monitor shunt flow would likely improve short- and long-term 
treatment options (Williams et al., 2007). Further, finding ways in which to reopen blocked 
pathways of CSF, similar to endoscopic third ventriculostomy, rather than inserting foreign 
objects into the body may reduce the need for recurrent neurosurgery. Optimizing treatment for a 
specific individual depending on the type of hydrocephalus present would also greatly improve 
outcomes following shunt surgery or ETV. 
 Improved early diagnosis is also necessary because the earlier hydrocephalus is treated, 
the better the outcome. Diagnosis of hydrocephalus is currently conducted using patient history, 
physical examination, imaging (US, CT and/or MRI) of the brain and measurements of ICP 
(Williams et al., 2007). Once ventriculomegaly is apparent and ICP is greatly elevated, the 
diagnosis of hydrocephalus is obvious; however, early hydrocephalus with mild to moderate 
ventriculomegaly and elevated ICP may be missed. Additionally, the classification of 
hydrocephalus, the decision of whether or not to treat the patient and the treatment best suited for 
the patient are often not straightforward. For example, compensated or arrested hydrocephalus in 
asymptomatic children and cerebral atrophy (hydrocephalus ex vacuo) in the elderly rarely 
require treatment; however, differentiating them from progressive hydrocephalus is often 
difficult (Williams et al., 2007). Detecting CSF flow and absorption abnormalities using MRI 
and infusion methods, respectively (Williams et al., 2007), may aid in the appropriate diagnosis 
and treatment. Further, identification of biomarkers, especially elevations of compounds in the 
CSF that can be identified by lumbar puncture, and improved behavioral and neuropsychological 
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testing may improve early diagnosis. Therefore, research into proteins elevated in the CSF of 
hydrocephalic individuals and the early behavioral and psychological changes found in patients 
with hydrocephalus will likely improve early diagnosis of this disorder and improve patient 
outcomes. 
 
b. The Ro1 model of hydrocephalus 
Advantages of the Ro1 model. Expression of the transgenic Gi-coupled Ro1 receptor selectively 
in GFAP-positive cells in mice results in communicating hydrocephalus with complete 
penetrance. Additionally, we are able to control the onset of hydrocephalus through the use of 
the tetracycline inducible system; removal of doxycycline from the drinking water of double-
transgenic mice results in Ro1 receptor expression and hydrocephalus. This model of 
hydrocephalus has a number of advantages. First, because all double-transgenic mice will 
develop hydrocephalus when taken off dox, we have the unique ability to study the earliest 
stages of hydrocephalus, which has provided insight into the pathogenesis of this disorder. 
Additionally, because hydrocephalus appears to be the primary pathology in this model, it is 
likely that any changes observed in this model are due to hydrocephalus and not the result of a 
secondary condition. No other animal model exists that allows for the investigation of early 
cellular changes in hydrocephalus without interference from secondary pathologies. Further, the 
selective expression of a Gi-coupled G protein-coupled receptor (GPCR) in GFAP-positive cells 
enables the investigation of specific signaling cascades in specific cell populations, providing a 
tractable model for determining the signaling cascades involved in the pathogenesis of 
hydrocephalus.  
 
 The Ro1 model of hydrocephalus also closely mirrors human hydrocephalus in many 
respects. In the Ro1 model, for example, we first see ventriculomegaly followed by the 
stretching and eventual loss of the ependyma layer. Further, the degree of ependymal loss 
appeared to be dependent on the rate of disease progression; when mice were maintained off dox 
throughout gestation, hydrocephalus appeared to develop more rapidly and ependymal loss 
appeared to be greater as compared to ventricles of equivalent sizes from mice taken off dox at 
P30. Multiple studies on humans have suggested that ependymal denudation is subsequent to 
ventriculomegaly, and the degree of denudation appears to be dependent on the size of the lateral 
ventricles and the rate at which hydrocephalus progresses; more rapid disease progression has 
been shown to increase ependymal loss (Bannister and Mundy, 1979; Bruni et al., 1985; Del 
Bigio, 1993; Sarnat, 1995). In the Ro1 model, we also showed through electron microscopy that 
reduced microvilli and cilia coverage of the ventricular walls as well as periventricular edema 
accompanied enlarged lateral ventricles and thinned ependymal linings. These changes have also 
been observed in humans with hydrocephalus (Bannister and Mundy, 1979; Bruni et al., 1985; 
DaSilva, 2004; Del Bigio et al., 1985; Di Rocco et al., 1977). Subependymal gliosis is also 
commonly observed in humans and animals with chronic hydrocephalus; however, gliosis has 
been shown to be subsequent to ependymal loss (Bruni et al., 1985; Del Bigio, 1993). Thus, 
although we did not observe gliosis early in the pathogenesis of hydrocephalus in Ro1 mice, a 
previous study using the Ro1 model demonstrated gliosis in the hippocampus and cortex of 
severely hydrocephalic Ro1 mice (Sweger et al., 2007), suggesting that gliosis occurs in Ro1 
mice with severe hydrocephalus. Although changes in the subventricular zone of human fetuses 
with moderate communicating hydrocephalus have also been observed, these changes were 
shown to be subsequent to ventricular dilation and ependymal loss (Dominguez-Pinos et al., 
 
2005). Therefore, it is possible that SVZ disorganization is also present in Ro1 mice, but only in 
mice with severe hydrocephalus and ependymal denudation, which was not investigated in this 
study. 
 
Disadvantages of the Ro1 model. Although all double-transgenic mice taken off dox will express 
the Ro1 receptor and develop hydrocephalus, there was considerable variability in the level of 
Ro1 expression and the rate of disease progression in double-transgenic mice. This is the greatest 
disadvantage of the Ro1 model because it impairs the investigation of the cellular and 
morphological changes present at a specific time point following the removal of dox. For 
example, at 30 d following the removal off dox from P30 mice, only two out of five double-
transgenic mice showed moderate to severe hydrocephalus (Table 4); the lateral ventricle to 
brain ratio of the remaining three double-transgenic mice was indistinguishable from single-
transgenic control mice. Thus, any tissue processed for histology or electron microscopy at a 
specific time point must take this variability into consideration. Additionally, it becomes nearly 
impossible to compare signaling changes between double-transgenic Ro1 mice and single-
transgenic controls via western blotting without correlating the changes in protein expression or 
phosphorylation to the severity of hydrocephalus in the same mouse. Therefore, by pooling 
ependymal and subependymal tissues from four different mice for the Kinexus antibody array 
and subsequent western blotting (as described in Chapter VII of this dissertation), any changes 
that might have been present at this time point would likely have been cancelled out due to the 
variability in disease progression among mice. (Here, it must be noted that the wrong cell 
population at the wrong time point was also likely isolated for these experiments. Please see 
Chapter VII for further explanation.) As a result, studies using the Ro1 model of hydrocephalus 
 
must take this variability into consideration and correlate cellular and histological changes to a 
marker of disease severity, such as the lateral ventricle to brain ratio. 
 
c. Possible signaling mechanisms 
The Ro1 receptor was created by removing the second extracellular loop of the kappa 
opioid receptor and replacing it with the second extracellular loop of the delta opioid receptor 
(Coward et al., 1998a; Redfern et al., 1999; Scearce-Levie et al., 2005; Sweger et al., 2007). 
Because both of these receptors are Gi-coupled GPCRs, it is likely that the Ro1 receptor also 
signals via Gi-coupled GPCR pathways. The major signaling pathways shown to be activated 
downstream of the KOR and other Gi-coupled GPCRs include inhibition of adenylyl cyclase, 
modulation of calcium and potassium channels and activation of the mitogen-activated protein 
kinase (MAPK) family, including ERK1/2, p38 and JNK (see Chapter VII for more detail on 
signaling pathways activated downstream of Gi-coupled GPCRs) (Bruchas and Chavkin, 2010). 
The Ro1 receptor has been shown to couple to adenylyl cylcase, causing a decrease in cAMP 
levels, providing further evidence that it couples to Gi-coupled signaling cascades (Coward et al., 
1998b). Additionally, cardiac arrhythmias caused by Ro1 expression in the heart were blocked 
by a single injection of pertussis toxin (PTX), demonstrating that Ro1 signaling through Gi-
coupled pathways in the heart caused this arrhythmia (Redfern et al., 2000). Further, previous 
studies in our laboratory have demonstrated upregulation of phospho-ERK around the lateral 
ventricle and entorhinal cortex of Ro1 mice (Sweger et al., 2007). Nonetheless, GPCR 
promiscuity has been demonstrated in other systems, especially upon overexpression of the 
receptor (Hermans, 2003); as such, with the high levels of expression and high basal activity of 
the Ro1 receptor, it is possible that receptor promiscuity is also occurring in our mice. 
 
Administration of PTX to Ro1 mice to determine whether Gi-coupled signaling cascades are 
necessary for the development of hydrocephalus in this model would therefore narrow our 
investigation of specific proteins involved in the pathogenesis of hydrocephalus to proteins 
involved in Gi-coupled GPCR signaling and thereby improve the likelihood of identifying 
therapeutic targets to treat this disorder. 
 
d. Future directions 
 The Ro1 model of hydrocephalus represents a unique tool for the study of hydrocephalus, 
and further studies using this model should focus elucidating signaling pathways involved in the 
pathogenesis of hydrocephalus and improving our understanding of the neuropathological 
changes that accompany this disorder. Determining how altered GPCR signaling cascades 
downstream of the Ro1 receptor lead to hydrocephalus should be a priority of future research. 
Due to the variability in Ro1 expression and the rate of progression of hydrocephalus in these 
mice, signaling changes will need to be correlated with Ro1 expression to determine when these 
signaling changes occur in the progression of this disorder. One method for doing this may be to 
coexpress green fluorescent protein (GFP) with Ro1 in GFAP-positive cells and use 
fluorescence-activated cell sorting to isolate GFAP-positive cells. This population can then be 
used to measure both Ro1 expression (either by real-time PCR or western blotting) and changes 
in signaling proteins via western blotting. Alternatively, fresh tissue can be isolated from one 
hemisphere of the Ro1 mouse brain for real-time PCR to determine levels of Ro1 expression, and 
the other half can be fresh frozen, fixed and processed for immunohistochemistry. Preliminary 
studies have suggested that this approach is feasible. Once signaling changes have been 
identified, administration of inhibitors to specific proteins believed to be involved in the 
 
pathogenesis of hydrocephalus will help to elucidate whether these proteins are necessary for the 
development of hydrocephalus. Intracerebroventricular infusions likely represent the best 
approach to selectively target these drugs to the brain and avoid non-specific and potentially 
deleterious systemic effects. Transgenic mice with cell- or brain-specific removal or 
overexpression for specific proteins could also be developed, although this approach is less 
feasible because the Ro1 mice are double-transgenic animals on a KOR knock-out background, 
and the breeding of mice with an additional transgenic construct could become complicated. 
 Further analysis of the pathological changes that occur in the brains of Ro1 mice would 
also be beneficial. For example, although we did not see any changes in the subventricular zone 
in early hydrocephalus in Ro1 mice, it is likely that changes in this region occur as 
hydrocephalus progresses. Also, investigating changes in adhesion molecules and cilia function 
could provide insight into early cellular changes that may contribute to the development of 
hydrocephalus. Further, it would be interesting and worthwhile to investigate changes in 
proteins, growth factors, neurotransmitters and other chemicals in the CSF of Ro1 mice through 
lumbar puncture and western blotting to better understand the early signaling changes in 
hydrocephalus and identify potential biomarkers for various stages of hydrocephalus. All of 
these changes should be correlated to Ro1 receptor expression to determine the timing and 
sequence of pathological changes in the Ro1 model of hydrocephalus. A better understanding of 
the neuropathological changes in the Ro1 model of hydrocephalus would improve our 
understanding of this disorder and possibly lead to the development of therapeutics to both 
prevent hydrocephalus and treat the adverse neuropathological changes that accompany this 
disorder 
 
 
e. Summary and conclusions 
 Hydrocephalus is a highly prevalent and devastating disorder for which the only 
treatment is recurrent neurosurgery to insert and revise shunts that drain the CSF. Better 
treatments are required for hydrocephalus, and the study of animal models of hydrocephalus will 
likely improve our understanding of the development and pathology of this disorder, leading to 
better diagnosis and treatments. The Ro1 model represents a unique model of hydrocephalus in 
that hydrocephalus can be induced at any age with complete penetrance and without interfering 
pathologies, enabling the investigation of the earliest pathological changes that lead to 
hydrocephalus. Also, the specific activation of a G-protein coupled receptor (the transgenic Ro1 
receptor) in a specific subset of cells (GFAP-positive cells) makes investigating signaling 
pathways involved in hydrocephalus extremely tractable.  The experiments presented herein 
provide insight into the previously unknown cellular and morphological changes that occur in the 
pathogenesis of the Ro1 model of hydrocephalus, which may lead to the development of 
pharmacological treatments for hydrocephalus. Additionally, the behavioral data suggest that 
treatments that slow the rate of progression of this disorder may have therapeutic potential by 
allowing the brain to compensate and increasing the therapeutic window for shunt placement or 
alternative treatments. 
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Figure 1. The ventricular system. The ventricular system is composed of four ventricles—two 
lateral ventricles, a third ventricle and a fourth ventricle—through which the cerebrospinal fluid 
(CSF) flows. CSF, which is produced primarily by the choroid plexus found in each of the four 
ventricles, flows from the lateral ventricles through the foramen of Monroe to the third ventricle 
and travels from the third ventricle through the aqueduct of Sylvius to the fourth ventricle. The 
CSF flows out of the fourth ventricle through the midline foramen of Magendie and two lateral 
foramina of Lushka into the cisterna magna and the basal cisterns of the subarachnoid space, 
respectively. The cavity of the fourth ventricle also extends into the central canal of the spinal 
cord. After exiting into the cisterna magna, the CSF then traverses the subarachnoid space over 
the surface of the cortex and drains back into the blood via the arachnoid granulations, spinal 
nerve roots and the olfactory tracts. Figure modified from Purves et al., 2001. 
 
 
 
Figure 2. The meninges. In this schematic, the inner surface of the skull is located at the top, 
and the external surface of the brain is located at the bottom. The meninges are composed of 
dura, arachnoid and pia mater, and a fluid-containing compartment called the subarachnoid space 
is present between the pia and arachnoid layers. Image reprinted from Haines et al., 1993. 
 
 
Figure 3. The Ro1 receptor. The Ro1 receptor was developed by replacing the second 
extracellular loop of the -opioid receptor with the second extracellular loop of the -opioid 
receptor. A FLAG tag was added to the N terminus for detection. The affinity of the Ro1 
receptor for endogenous ligands is greatly reduced; however, it still responds to the small 
molecule drug spiradoline and the antagonist norbinaltorphamine (norBNI). Figure modified 
from Coward et al., 1998. 
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Figure 4. The tet-off system. Ro1 mice were created by crossing two lines of mice: in one line 
the GFAP promoter drives tTA expression. In the other line the tetO minimal promoter drives 
Ro1 expression. In the absence of doxycycline, tTA binds to the tetO promoter, driving Ro1 
expression to GFAP+ cells. When mice are given dox, the dox binds to tTA, preventing tTA 
binding to the tetO promoter and thereby blocking Ro1 expression. Figure modified from 
Scearce-Levie et al., 2001. 
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Figure 5. The Ro1 receptor is selectively expressed in astrocytes. Hippocampal brain sections 
were double-stained for FLAG and GFAP (astrocyte marker) or FLAG and NeuN (neuronal 
marker). A) FLAG staining (left, arrow) was colocalized with GFAP (right, arrow) but not with 
NeuN (B). The arrows point to the same cell. Scale bars, 100 m. Figure reprinted from Sweger 
et al., 2007. 
 
 
Figure 6. Ro1 expression can be regulated by doxycycline. Brain lysates from a C57BL/6 
control mouse, an Ro1 mouse maintained on dox (25 g/ml) and Ro1 mouse maintained off dox 
were immunoprecipitated with a FLAG monoclonal antibody and subjected to western blotting 
using a FLAG polyclonal antibody. Only the Ro1 mouse maintained off dox showed FLAG-
tagged Ro1 expression. A nonspecific band was found in all samples (arrowhead). Br, Brain; 
Hipp, hippocampus; Ce, cerebellum. Figure reprinted from Sweger et al., 2007. 
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Figure 7. Survival curve of Ro1 mice maintained off doxycycline. All Ro1 mice maintained 
off dox develop hydrocephalus, and >50% die by 12 weeks of age. Figure reprinted from Sweger 
et al., 2007. 
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Figure 8. Signaling through the Ro1 receptor causes hydrocephalus. Mice were maintained 
on dox, taken off dox at P30 or taken off dox at P30 and given injections of norBNI (7.6 mg/kg 
i.p.) every three days for 30 days. At P60, the mice were sacrificed and the lateral ventricle to 
brain ratio was measured. Ro1 mice off dox for 30 days showed significantly greater lateral 
ventricle to brain ratios than control mice; there were no significant differences between controls 
or Ro1 mice maintained on dox or taken off dox for 30 days and given norBNI. Figure courtesy 
Sweger and McCarthy, 2009. 
 
 
Figure 9. Phospho-ERK is upregulated in mice with hydrocephalus. Increased phospho-Erk 
staining was observed around the lateral ventricles (B) and in the entorhinal cortex (D) of 
hydrocephalic Ro1 mice but not in littermate controls (P21, always off dox) (A, C). No increases 
in phospho-Erk were observed in the hippocampus (F). Sections shown in A and B are at the 
level of the anterior commissure and striatum; C–F are at the level of the subcommissural organ. 
Scale bars, 150 m. LV, Lateral ventricle; DG, dentate gyrus. Reprinted from Sweger et al., 
2007. 
 
 
 
Figure 10. Variable expression of Ro1 receptor mRNA in Ro1 mice at 9 days off dox. Real-
time PCR was used to measure Ro1 receptor mRNA expression levels using human KOR 
primers in lysates isolated from mouse brain tissue. This graph shows the relative quantification 
of Ro1 receptor expression in Ro1 mice and littermate controls (n = 6). Although Ro1 receptor 
mRNA was clearly expressed by Ro1 mice by 9 days after the removal of dox at P30, there was 
considerable variability in the levels of Ro1 mRNA expression among Ro1 mice. 
 
Figure 11. Lateral ventricle size increases as hydrocephalu
At 9 (A), 12 (B) and 18 (C) days off dox, there were no changes in lateral ventricle (LV) size 
between Ro1 mice and littermate controls. (At 18 d off dox, the average LV:brain ratio = 0.20 
and 0.14 for control and Ro1 mice, r
ventricle size were first observed at 24 days off dox (D; The average LV:brain ratio = 0.14 and 
0.22 for control and Ro1 mice, respectively; range (Ro1) = 0.14 

s progresses in the Ro1 model.
espectively; range (Ro1) = 0.10 – 0.18.) Increases in 
– 0.39). Ventriculomegaly 
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became increasingly more severe as hydrocephalus progressed; (E) 30 days off dox (The average 
LV:brain ratio = 0.14 and 0.25 for control and Ro1 mice, respectively; range (Ro1) = 0.15 – 
0.43), (F) 48 days off dox (The average LV:brain ratio = 0.18 and 0.32 for control and Ro1 mice, 
respectively; range (Ro1) = 0.18 – 0.64). Scale bar = 1.0 mm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Progressive disorganization of the aqueduct of Sylvius occurs in the Ro1 model.
At 9 (A), 12 (B) and 18 (C) days off dox, there were no changes in the ependymal lining of the 
aqueduct between Ro1 mice and littermate controls. Disorganization of the ependymal lining of 
the aqueduct was first observed at 24 days off dox (D). This disor
more severe as hydrocephalus progressed and lateral ventricle size increased; (E) 30 days off 
dox, (F) 48 days off dox. These images were taken from the brains of the same Ro1 mice shown 
in Figures 2 and 5. Scale bar = 100 
 

ganization became increasingly 
m. 
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Figure 13. Lateral ventricle size is correlated with the degree of aqueduct disorganization. 
In Ro1 mice, lateral ventricle size is significantly correlated to disorganization of the aqueduct of 
Sylvius (r2 = 0.67; p < 0.0001). As lateral ventricle size increased, the aqueduct became 
increasingly disorganized. 
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Figure 14. Changes in the ependymal lining of the ventricles are subsequent to 
ventriculomegaly. There were no changes in the ependymal lining of the lateral ventricles at 9 
(A), 12 (B) or 18 (C) days off dox. As the lateral ventricle size increased, the ependymal layer 
became thinner; (D) 24 days off dox, (E) 30 days off dox and (F) 48 days off dox. These images 
were taken from the lateral wall of the left lateral ventricle. These images were 
brains of the same Ro1 mice shown in Figures 2 and 3. Scale bar = 20 
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Figure 15. Lack of cellular changes in subventricular zone organization in early 
hydrocephalus in Ro1 mice. (A) and (B) show GFAP (green) and S100 (red) expression at 9 
days off dox in control and Ro1 mice, respectively (n = 4; scale bar = 50 m). (C) and (D) show 
GFAP (green) and S100 (red) expression at 12 days off dox in control and Ro1 mice, 
respectively (n = 3; scale bar = 100 m). (E) and (F) show GFAP (green) and S100 (red) 
expression at 24 days off dox of control and Ro1 mice, respectively (n = 5; scale bar = 200 m). 
These images were taken from the right lateral ventricle in coronal slices. There were no 
detectable changes in GFAP or S100 expression at any time point analyzed. (G) and (H) show 
DCX (red) expression from the lateral ventricle to the olfactory bulb in sagittal sections from 
control and Ro1 mice, respectively, at 24 days off dox. There were no detectable changes in 
DCX expression or migration at 24 days off dox (n = 5; scale bar = 100 m). 
 
 
 
 
 
 
 
 
Figure 16. Ultrastructural changes in the periventricular region in Ro1 mice.
Ventriculomegaly leads to thinning of the ependymal layer, which w
and patches of the ventricular wall barren of microvilli. A control (A) and two Ro1 (B and C) 
mice at 30 days off dox are shown (n = 3). Ro1 mice showed considerable thinning of the 
ependymal layer and a reduction in the number of 
In the Ro1 mouse with an enlarged head and moderate ventriculomegaly (B), spaces appear to be 
developing between cells (white arrows). In the Ro1 mouse with an enlarged head and severe 
ventriculomegaly (C), vacuoles were present in the ependymal cell cytoplasm, and edema was 
present in the subependymal area (EF = edematous fluid). These images were taken from the 
lateral wall of the lateral ventricle. Scale bar = 2 
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as associated with edema 
microvilli lining the ventricles (black arrows). 
m. 
 
 
Figure 17. Morphological changes 
off dox. The progression of hydrocephalus in mice maintained off dox throughout gestation and 
development mirrors that found in mice taken off dox at P30. Images of coronal brain slices (A, 
D and G; scale bar = 1.0 mm), the lateral wall of the right lateral ventricle (B, E and H; scale bar 
= 50 m) and the aqueduct of Sylvius (C, F and I; scale bar = 50 
mouse (A – C) and two Ro1 mice (D 
enlargement of the lateral ventricles (D and G), thinning (E) or loss (H) of the ependymal layer 
and disorganization of the ependymal lining of the aqueduct (F and I). The average LV:brain 
ratio was 0.34, and the range = 0.18 
 

in the progression of hydrocephalus in mice maintained 
m) are shown from a control 
– F and G – I) at P27. Ro1 mice showed
– 0.64. (n = 4) 
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Figure 18. There are no differences in weight between Ro1 mice and littermate controls up 
to seven weeks following the removal of dox. Weight was measured weekly following the 
removal of dox from Ro1 and control mice at P30. p = 0.90. Control, n = 11; Ro1, n = 10. 
 
 
Figure 19. There are no differences in the total distance traveled between Ro1 mice and 
littermate controls up to seven weeks following the removal of dox. Total distance traveled 
was measured weekly in an open field activity box following the removal of dox from Ro1 and 
control mice at P30. p = 0.62. Control, n = 11; Ro1, n = 10. 
 
 
Figure 20. There are no differences in rotarod performance between Ro1 mice and 
littermate controls up to seven weeks following the removal of dox. Performance for a 
maximum of five minutes on an accelerating rotarod was measured twice weekly. Data from 
each trial were averaged for each week. p = 0.22. Control, n = 11; Ro1, n = 10 
 
 
Figure 21. There are no differences in the startle response between Ro1 mice and littermate 
controls up to seven weeks following the removal of dox. Startle responses to a 120 dB 
acoustic stimulus were measured every week for seven weeks. p = 0.23. Control, n = 11; Ro1, n 
= 10. 
 
 
Figure 22. There are no differences in grip strength, as measured by the wire hang test, 
between Ro1 mice and littermate controls up to seven weeks following the removal of dox. 
The latency to fall off of a wire grid, with a maximum cut-off time of 60 seconds, was measured 
weekly for seven weeks. Control, n = 11; Ro1, n = 10. 
 
 
Figure 23. There are no differences in the latency to find the hidden platform in the Morris 
water maze test between Ro1 mice and littermate controls at 15 – 19 days off dox. The 
latency to find a hidden platform was tested over four consecutive days until the mice, as a 
group, reached the platform in less than 15 seconds. p = 0.60. Control, n = 11; Ro1, n = 10. 
 
 
Figure 24. There are no differences in the hidden probe trial between Ro1 mice and 
littermate controls at 19 days off dox. The time spent in the quadrant where the escape 
platform had been previously located during the hidden acquisition trials was measured. p = 
0.86. Control, n = 11; Ro1, n = 10.  
 
 
Figure 25. There are no differences in the latency to find the hidden platform during the 
reversal learning trials between Ro1 mice and littermate controls at 22 – 32 days off dox. 
The latency to find a hidden platform was tested over nine consecutive days until the mice, as a 
group, reached the platform in less than 15 seconds. p = 0.93. Control, n = 11; Ro1, n = 10. 
 
 
Figure 26. There are no differences in the reversal probe trial between Ro1 mice and 
littermate controls at 32 days off dox. The time spent in the quadrant where the escape 
platform had been previously located during the reversal learning trials was measured. p = 0.17. 
Control, n = 11; Ro1, n = 10.  
 
 
Figure 27. There are no significant differences in memory retention between Ro1 mice and 
littermate controls at 46 – 47 days off dox. After two weeks spent in their home cages, the 
mice were returned to the pool, and their latency to reach the hidden platform was recorded. The 
platform’s location was the same as in the reversal learning trials. p = 0.26. Control, n = 11; Ro1, 
n = 10. 
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Figure 28. Lateral ventricle size is correlated to latency to find the hidden platform at 46 
days off dox. Testing for memory retention of the location of the hidden platform was performed 
two weeks following the reversal probe trial. There was a moderate, but significant, correlation 
between the lateral ventricle to brain ratio and the latency to find the hidden platform at 46 days 
off dox (retention, trial 1), suggesting reduced memory in Ro1 mice (r2 = 0.59; p = 0.026). 
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Figure 29. There are no differences between Ro1 mice and littermate controls in the 
elevated plus maze at 24 days off dox. Time spent in the open arms was recorded during a 5-
min period on the elevated plus maze. p = 0.78. Control, n = 17; Ro1, n = 13. 
 
 
Figure 30. There are no differences between Ro1 mice and littermate controls in the forced 
swim test at 25 days off dox. Time spent immobile during a 6-min period was recorded. p = 
0.66. Control, n = 17; Ro1, n = 13. 
 
 
Figure 31. There are no differences between Ro1 mice and littermate controls in the time 
spent in the center of an open field at 31 days off dox. Center time was measured in 5-min 
bins over a 60 min period. p = 0.33. Control, n = 17; Ro1, n = 13. 
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Figure 32. There are no differences in passive avoidance between Ro1 mice and littermate 
controls at 33 days off dox. On the first day of testing, mice learned to associate a mild 
footshock with the dark chamber. The change in latency to enter the dark chamber between the 
two days was recorded. p = 0.45. Control, n = 17; Ro1, n = 13. 
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Figure 34. Ro1 receptor mRNA is highly expressed in primary astrocyte cultures from Ro1 
pups maintained off dox, but not in cultures from littermate controls. Real-time PCR was 
used to measure Ro1 receptor mRNA expression levels using human KOR primers in lysates 
isolated from primary astrocyte cultures. 
 
 
Figure 35. Cultured primary astrocytes express the Ro1 receptor. Staining for GFAP-
positive cultured astrocytes (green) showed colocalization with the FLAG-tagged Ro1 receptor 
(red). 
 
 
Figure 36. Aquaporin 4 levels show a decreasing trend in Ro1 mice as compared to 
littermate controls at 18 d off dox. Immunohistochemistry for aquaporin 4 was quantified in 
the ependymal and subependymal regions using MatLab software to analyze staining intensity 
over background. p = 0.21, n = 12. 
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